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INTRODUCTION
Genetic testing is now such a widespread and important part of medicine that it
is hard to realize that it has almost all emerged during the past 30 years, with
most of the key workers responsible for the discoveries and development of the
field still living and active.
This alone makes it a suitable subject for a Witness Seminar but there are others that
increase its value, notably the fact that a high proportion of the critical advances
took place in the UK; not just the basic scientific research, but also the initial
applications in clinical practice, particularly those involving inherited disorders.
To see these topics discussed by the people who were actually involved in their
creation makes fascinating reading; for myself it is tinged with regret at having
been unable to attend and contribute to the seminar, but with some
compensation from being able to look at the contributions more objectively than
can a participant.
This Witness Seminar reminds us of the broad scientific origins of human
genetics, involving not only chromosomal and molecular technologies, but
blood groups, immunological and biochemical approaches, as well as the
theoretical basis of genetic linkage analysis.  It is the synthesis of all of these and
their use in a medical context, that has made the field such a rewarding one to
work in, as well as one that has had major benefits for patients and families.  So
has its strongly collaborative and generous nature, something that is clearly
reflected throughout this volume.
The one element largely absent from this seminar is the field of clinical genetics,
but the organizers were probably wise not to attempt to include this, as they have
had more than ample material by staying with the scientific brief of genetic
testing.  I sense that strict chairmanship was required to avoid discussions that
could have occupied a week, not a day, so perhaps clinical genetics will merit its
own Witness Seminar in the future.  Meanwhile, all those who wish to know
how genetic testing originated and developed will find many of their questions
answered in the following pages.
Peter Harper
University of Wales College of Medicine, Cardiff
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1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to
Twentieth Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the
History of Medicine at University College London.
WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine
Group, as part of the Academic Unit of the Wellcome Institute for the History
of Medicine, to bring together clinicians, scientists, historians and others
interested in contemporary medical history. Among a number of other initiatives
the format of Witness Seminars, used by the Institute of Contemporary British
History to address issues of recent political history, was adopted, to promote
interaction between these different groups, to emphasize the potential of
working jointly, and to encourage the creation and deposit of archival sources for
present and future use. In June 1999 the Governors of the Wellcome Trust
decided that it would be appropriate for the Academic Unit to enjoy a more
formal academic affiliation and turned the Unit into the Wellcome Trust Centre
for the History of Medicine at University College London from 1 October 2000.
The Wellcome Trust continues to fund the Witness Seminar programme via its
support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several
people associated with a particular set of circumstances or events are invited to
come together to discuss, debate, and agree or disagree about their memories. To
date, the History of Twentieth Century Medicine Group has held over 30 such
meetings, most of which have been published, as listed on pages xiii–xix.
Subjects for such meetings are usually proposed by, or through, members of the
Programme Committee of the Group, and once an appropriate topic has been
agreed, suitable participants are identified and invited. These inevitably lead to
further contacts, and more suggestions of people to invite. As the organization
of the meeting progresses, a flexible outline plan for the meeting is devised,
usually with assistance from the meeting’s chairman, and some participants are
invited to ‘set the ball rolling’ on particular themes, by speaking for a short
period of time to initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited
transcript is immediately sent to every participant. Each is asked to check their
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own contributions and to provide brief biographical details. The editors turn the
transcript into readable text, and participants’ minor corrections and comments
are incorporated into that text, while biographical and bibliographical details are
added as footnotes, as are more substantial comments and additional material
provided by participants. The final scripts are then sent to every contributor,
accompanied by forms assigning copyright to the Wellcome Trust. Copies of all
additional correspondence received during the editorial process are deposited
with the records of each meeting in Archives and Manuscripts, Wellcome
Library, London. 
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the nonspecialist, the sense and significance of
the events are understandable. Our aim is for the volumes that emerge from
these meetings to inform those with a general interest in the history of modern
medicine and medical science; to provide historians with new insights, fresh
material for study, and further themes for research; and to emphasize to the
participants that events of the recent past, of their own working lives, are of
proper and necessary concern to historians.
xii
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Dr Daphne Christie: The History of Twentieth Century Medicine Group was
established by the Wellcome Trust in 1990, to promote interaction between
scientists, clinicians, and historians who have a common interest in the history
of recent medicine and medical science. To that end this group has devised a
number of mechanisms to try to promote that interaction, one of which is a
series of Witness Seminars, where we invite people who have been involved in
particular events, or discoveries, or who have seen a lot of changes during their
working lives in practice, to discuss, debate, and to share with us their
reminiscences and views of how things were and how things have changed. 
Professor Doris Zallen and I have organized this meeting on genetic testing, and
we are very grateful to Doris for her help and for travelling from the USA to be
with us today. Doris will give a brief historical introduction to the subject in a
few minutes’ time. A key part in these meetings is in identifying a suitable
chairman, and we are indeed delighted that Professor Pembrey has agreed to
chair this one, so without further ado, I will hand over to the Chairman.
Professor Marcus Pembrey: Thank you very much. Welcome everybody. This
is an informal occasion, and although I am going to try to move the programme
through and keep you reasonably on track, the idea is to have anecdotes and
exchanges that can record ‘how it was’. 
In thinking about when genetic tests started and what were the early genetic
tests, I thought that we needed to have some kind of a definition to show that
we are not talking about a clinical diagnosis of a genetic disorder, but a test that
was pretty specific, with high predictive value, for either confirming or excluding
a known specific genetic disorder, or a genetic trait, like a blood group. So
thinking back, the screening as I know that went on under Lionel Penrose’s
direction in the Royal Eastern Counties’ Institution in Colchester in the 1930s,
of the urines of mentally handicapped patients for phenylpyruvic acid would fit
the definition of a genetic test.1 It was a particular thing that they had in mind,
as with blood grouping. The other thing I recognize is that up until the precision
of clear chromosomal abnormalities and DNA changes, a lot of the tests had to
take in prior probability, that is the test was useful only because of the family
history, the context in which it was done. So clearly we are not just talking about
genetic tests but to some extent clinical genetic services as well.
Genetic Testing
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1 See Penrose (1935a, 1935b); Harris (1973): 523–529. Further details are given in a letter from
Professor Marcus Pembrey to Dr Daphne Christie, 5 August 2003, which will be deposited with the
records of the meeting in Archives and Manuscripts, Wellcome Library, London.
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In thinking about how things began, clearly this was dictated largely by the available
material, which was blood, and so later on, after Doris has given her introduction,
we will be following, as an initial introduction, those two areas that came out of
blood, the blood groups and the blood diseases on the one hand, and the peripheral
blood lymphocytes as a source for looking at chromosomes and chromosomal
changes on the other, and then leading obviously through the programme. Does
anybody have any questions about the field, the terms of reference?
Professor Doris Zallen: I have been assigned to start the ball rolling with a
scientific and historical introduction. I will keep it brief because the real experts
are sitting in front of me. It’s often very hard for historians to pick a particular
date for the start of a field, but that’s not the case in genetics. Historians of science
all trace the start of the field to the year 1900, with the rediscovery of Mendel’s
laws. As you know, Mendel explained the patterns of inheritance he observed in
pea plants by hypothesizing the existence of paired factors.2 This rediscovery
triggered a growth in research regarding the nature of those factors – research on
all kinds of organisms – that intensified through the rest of the century. 
By mid-century, genetic research received an additional boost when DNA was
found to be the material of these factors, now called genes, and the structure of
the molecule was worked out at Cambridge.3 Then, in the 1960s, came the work
that led to the understanding of the mechanism of gene function, of the triplet
nature of the genetic code, and the first insight into regulation of genes in
bacteria.4 The knowledge generated in the laboratory often spun off other
programmes of research with more practical ends. For example, genetics in the
USA found a home, almost immediately after the rediscovery of Mendel’s work,
in agricultural research stations, located in every state in the country. That firm
base of support and connection with the farming community, a community
which wanted specific findings from science to help their work, encouraged the
development in the USA of a large research effort dealing with the development
of better crop plants and farm animals, of organisms with new combinations of
traits. We are seeing the end-product of that now, with genetically modified
foods that are the subject of debate around the world.5 So much of the ground-
Genetic Testing
4
2 Mendel (1865).
3 Watson and Crick (1953).
4 Jacob and Monod (1961, 1962); Crick et al. (1961); Nirenberg and Matthei (1961); Nirenberg and
Leder (1964); Clayton and Dennis (2003).
5 Soulsby (1997). 
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breaking work in genetics was carried out by scientists in Britain, I have a very
long list – I will give you a few names that I know are familiar to all of you:
names like Galton, Bateson, Pearson, Haldane, Fisher, Hardy, Ford, Sheppard,
Crick, Franklin, Wilkins, Brenner, Sanger. A lot of the basic work was done here.
Research in human genetics generally lagged well behind that of other organisms
and for obvious reasons: the small number of progeny, the long generation time,
and the decided unwillingness of humans to submit to planned rounds of sexual
crosses at the whim of investigators. As a result, applications of genetics to
medicine tended to be scarce. Yet with the advent of new tools – of cytogenetic
and recombinant DNA techniques, both of which made sex unnecessary – this
was to change. The increasing pace of research in human genetics has culminated
in the boldest project of all, the International Human Genome Project, which in
2000 provided the first rough draft of the entire human DNA base sequence.6 In
just one century from the start in 1900, genetics has come a long way. Even
before the Human Genome Project itself, genetics had begun to enter medicine,
and we have seen that with the rise in the use of genetic testing. This has led to
the prediction that the 21st century will see the growth and expansion of what
we now call genetic medicine, that it will be a time in which genetic testing will
be routinely offered, a time in which medicine will be operating under a new
genetic paradigm, and in which testing for disease prevention will be a dominant
activity. Once again, scientists and physicians in Britain have had a major
involvement in the evolution of genetic medicine. Garrod, Haldane, Fisher,
Penrose, Harris, Lawler, Clarke, as well as many of the individuals in this room,
have created the environment in which this change has taken place.
Our goal today is to track the separate developments that have crystallized into
genetic medicine by examining the various foci, the various nuclei of research
and application. We have the rare opportunity to benefit from your experience
and your recollections. We need to find out what happened, and, beyond that,
we need to try to explain how it happened. For example, was there a prevailing
conceptual apparatus? Was there a set of ideas, related to polymorphisms, which
guided the work? Were there particular techniques or modes of analysis that
spurred the work? Were there institutional factors such as the gathering together
in one place of a critical mass of people with a critical set of skills? Were there
perhaps societal trends or policies that contributed to the moulding of research
agendas or the translation of research findings into clinical applications? 
Genetic Testing
5
6 Anon. (2001).
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In line with that I will just mention the eugenics movement. The governmental
policies associated with the eugenics movement in the USA, which came with
such things as involuntary sterilization, have left a cloud over research in human
genetics and in applications to medicine. Was there such a cloud here? Historians
have said that though the eugenics movement started in Britain, it didn’t lead to
any real governmental policies, and so perhaps being spared the taint of eugenics
has helped spur research and the development of genetic medicine in this
country. Those are the factors we need to explore along with the specific events
themselves. I think the discussion today may help us understand not only how
we got to this point in time with genetic medicine, but may hint at some of the
directions that the field is likely to take in the future. 
Pembrey: Thank you very much, Doris. Your mention of the link with
agriculture at the beginning reminds me that John Fraser Roberts, who was one
of my mentors, started off in Edinburgh looking at the genetics of sheep and
things like that.7 There’s a nice anecdote about J B S Haldane: they didn’t get on
very well later on, and I had it explained that at one stage John Fraser Roberts had
described a pattern on the face of a sheep that was linked to wool quality, so it was
useful, and he decided to call it reverse badger face, because there was a badger-
faced sheep, and this seemed to be the opposite. Apparently from then on J B S
Haldane used to refer to him as old reverse badger face, and if anybody knew John
he didn’t like that sort of thing. Another mentor was Paul Polani and he has kindly
agreed to give a historical perspective before we get into more of a free-for-all.
Professor Paul Polani: Opening on cytogenetics, I present here a sketchy and
condensed view of the importance that chromosomes have had in the modern
scientific developments and practical application of human genetics.8
So may I start with a few critical dates and names? The starting date is 1956
when Tjio and Levan revealed the number of chromosomes to be 46 in cultured
somatic cells – a finding that broke the technical problem of chromosome
handling, as well as the spell of magic 48.9 Also in 1956 number 46 was
confirmed in vivo by the techniques that Charles Ford and John Hamerton
employed on human male meiotic cells at metaphase.10 Then came 1959 with
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the discovery of chromosome anomalies, both gono- and autosomal, both
numerical and structural. This search was guided by a number of clear clinical
indications on where best to harvest, well before chromosome work could be
applied effectively to human affairs, using the new techniques that have been
alluded to by Marcus Pembrey in his introduction.11
We can then skip to the early 1970s, namely to the work of Caspersson and
Zech12 with quinacrine fluorescent banding, and to this easier and more
complete chromosome identification method than the autoradiography one.
Chromosome identification was subsequently made more practical by G
banding and reverse banding. 
One can truly say that the scientific uses and practical application of
chromosomology revolutionized human genetics and took it out of doldrums, that
had been partly due to the influence of eugenics, partly due to technical
inadequacies, especially, it was felt, of cytological methods. Medicine too had to
come to grips with the practical uses of cytogenetics and genetics in the clinic, and
so came to realize its fundamental contribution to basic science, level with anatomy
and physiology. So the new disciplines of clinical and medical genetics were born. 
Although there are many derivatives of the cytogenetic explosion, I discern at least
five main lines of descent, and I will look at each of them fairly briefly. The first
one was the change of the formal genetics of human sex determination, or
primary sexual differentiation, already implied in our 1954/56 work on Turner
syndrome females, considered quite plausibly to be XO,13 as well as the studies on
Klinefelter syndrome males14 running in parallel and using in both cases sex
chromatin as a cell marker, and colour vision/colour blindness as a genetic marker
for the X chromosome. In 1959 as a result of direct X chromosome studies of
these two human sex errors, the XO constitution was confirmed in females with
Turner syndrome, and the XXY status of males with Klinefelter’s syndrome was
sorted out by the work of Jacobs and Strong, and by Ford and ourselves.15 Thus
the Drosophila sex determination pattern, which was a dogma for humans in those
days, had to be abandoned in favour of the mammalian Y chromosome as the key
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sex determiner – the so-called Melandrium pattern. At the same time the reality
in humans of chromosome mosaicism was objectively demonstrated.
Later, from 1990, the molecular story of Y-chromosomal control on primary sex
determination was being written, to begin with largely by Gubbay, Sinclair, Lovell-
Badge and Goodfellow,16 aided by the observations of Jacobs and Ross on the Y
chromosome and those of Ferguson-Smith on XX males with Klinefelter syndrome17
and ourselves on XY females, often with pure gonadal dysgenesis (Swyer syndrome).18
The second leitmotif is Mary Lyon’s ‘inactive-X hypothesis’,19 proposed in 1961,
partly from XO human and murine females, partly from the study of mouse coat
colour marker genes, and partly from the heterochromy of one X in XX subjects,
studied especially by Ohno, and its late DNA synthesis investigated by Taylor
and colleagues.20 Following the pinpointing of the X inactivation (initiation)
centre (XIC/Xic) and then the discovery of the influence of the inactivation
control centre (Xce) which affects randomness of X chromosome inactivation,
lyonization20a is a good way towards its molecular resolution, particularly now
that the work of Brown and Ballabio on XIST/Xist has identified a control
mechanism on the X chromosome which seems to supersede the need to
suppress or modulate the activity of individual X-linked genes.21
The third line of descent follows the fortunes of somatic-cell hybridization in
vitro, which transformed human genetics into an experimental science by
bypassing, as Pontecorvo was wont to stress, the key obstacle of sexual
reproduction. Cells had been fused since 1960 by Barski first and then by
Ephrussi and Sorieul,22 but what was really of interest to humans was the
production of human/mouse cell hybrids by Weiss and Green in 1967,23 which
were applied to the mapping of human chromosomes. The first assignment was
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the thymidine kinase gene to an E group chromosome. This was later identified
precisely, as required for mapping, as chromosome 17 by Miller in 1971:24 ‘The
first swallow that made summer’, as Henry Harris described the event. 
The cell fusion work led not only to the mapping of genes by chromosome
assignment, but also and importantly to the production of monoclonal antibodies
by Köhler and Milstein in 1975; while from 1969 it led to the analysis of
suppressor genes in human malignancy, especially by the work of Henry Harris.25
Which brings me to the fourth line of descent from cytogenetics, namely to its
contribution to the attack on malignant transformation, which technically runs
in parallel, side by side, with the isolation of genes not related to neoplasia. The
modern side of the chromosomes and cancer theory begins in 1960 with the
demonstration by Nowell and Hungerford of the ‘Philadelphia’ marker
chromosome in chronic myeloid leukaemia.26 This was later found by Janet
Rowley to be the result of a translocation between chromosome 9 and 22,
subsequently unravelled at the molecular level with the application of the
recombinant DNA methods of the ‘new genetics’.27 Originally the cytogenetic
analysis of solid tissue malignancies was conveniently based on the study of the
1 or 2 per cent simple mendelizing conditions with susceptibility to malignancy,
perhaps some 50 syndromes in all: such as, for example, the childhood cancers,
like retino- and nephroblastoma or colorectal cancers in adults. Taking
retinoblastoma as an example, in 1963 a case of this tumour was described by
Lele, Penrose and Stallard with a deletion in the long arm of a D-group
chromosome, but the structural change was considered fortuitous.28 However,
Wilson reported another example in 1969, and in the same year a review by
ourselves of chromosome abnormalities identified other examples of D-group
deletions in retinoblastoma;29 in 1971 the relevant chromosome was identified as
number 13.30 There followed the identification of the mutant gene (recessive at
the cell level) at the site of the chromosome break and the mechanism of how it
was involved in the ocular malignancy in children – with general implications for
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malignant transformation, largely in line with Knudson’s ideas on sequential hits
as the origin of malignancy.
The search for chromosomal loci related to malignant transformation was
accelerated through the study of natural structural chromosome errors, like
translocations or deletions, which would segregate with the malignancy
phenotype. In this way many specific chromosome regions involved in
malignancy have been pinpointed, opening the way to their molecular analysis
and gene identification.
The same approach was used for the isolation of many major genes not related
to neoplasia, such as cystic fibrosis or, with a difference too, for
Duchenne/Becker muscular dystrophy.31
Further development of cytogenetic analysis – my fifth line of descent – will
depend in great part on the adoption of new techniques to increase precision and
resolution power, particularly at the moment through the improvement of
banding methods; the introduction of methods derived from recombinant
DNA, such as, at present, the polymerase chain reaction [PCR]; and of specific
DNA probes. These two techniques are often combined to produce high-
resolution fluorescent in situ hybridization methods that are acronymed FISH,
or multicolour FISH. The consequent expansion of in situ work, both metaphase
and interphase, and not only of somatic cells but also of cells of the germ line,
particularly those involved in spermatogenesis, has yielded important
information, both theoretical for research and practical for application; for
example, in prenatal diagnosis, in cancer research, in the investigation of
infertility, and in the study of unclassified mental retardation. As examples of the
latter search one may mention studies aimed at detecting subtelomeric
chromosome rearrangements, namely rearrangements in the gene-rich telomeric
regions of chromosomes. One notes that telomeres seem also relevant to cancer
research, to research on ageing, and perhaps as counters and recorders of
numbers of cell divisions. 
Finally, a few words on the origins of trisomy 21, as a representative of all
trisomies, which are about one-third of all recognized pregnancies in women
over the age of 40. Only a small proportion of trisomy 21s are inherited in a
maternal-age-independent manner through centromeric fusion translocation, as
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we showed in 1959 and 1960.32 Disregarding the 10 per cent paternal
contribution to the origin of trisomy 21, maternal-age dependence of
nondisjunction of chromosome 21, which lies at the origin of trisomy, seems to
result either from the failure of chromosomes 21 to cross-over and recombine at
meiosis, or from a mislocation of chiasma position. The result of either is an error
of chromosome partitioning at the first or second meiotic divisions of the mature
ovum before or at sperm penetration and fertilization. In either case, namely
when no chiasmata form or when chiasmata are mislocated, we know that these
recombination errors take place at the meiotic prophase, which, on the female
side, is in fetu well before she is born, and thus long before she becomes a mother.
The fact that meiotic recombination errors in fetu are revealed in ova matured and
released at advancing maternal age might support the idea that oogenesis follows
a production line system. This hypothesis was proposed by Henderson and
Edwards in 196833 and, in essence, it says that early entry into meiosis in fetu
corresponds to exit of the mature ovum soon after puberty, whereas late entry into
meiosis in fetu yields ova that exit at a late maternal age, a case of first in first out,
last in last out; a hypothesis which is supported by our animal experiments.34
Pembrey: Thank you very much for that broad historical introduction. We are
going to be coming back to cytogenetics after this historical scientific overview
to tease out the players in cytogenetics, as applied to clinical genetic testing and
so on. Down’s syndrome is so central to that and to prenatal diagnosis and so on.  
Before we get on to the specifics and to the names of the people who were
involved in this, and to the groups, I think, just to give the other general broad
historical perspective, David Weatherall would be prepared to say a bit on the
haemoglobinopathy side, because that work very definitely, with the blood
groups, led a parallel background into what then became clinical genetic testing. 
Professor Sir David Weatherall: I believe it was the Churchillian view that the best
extemporary speeches are made after six months’ notice; I have had just six minutes,
but I will do my best. In essence, the pattern of development in the
haemoglobin–genetics field was similar to that just described by Paul Polani – that
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is, it was very much technology driven. The two important haemoglobin disorders,
the thalassaemias and sickle-cell diseases, were described between 1925 and 1932 in
the USA and their genetics worked out over subsequent years by workers in the
USA, Africa and Italy.35 In the late 1940s, Linus Pauling, following a suggestion by
Bill Castle of Boston, asked one of his students, Harvey Itano, to examine the
haemoglobin of patients with sickle-cell anaemia using the recently developed
technique of moving-boundary electrophoresis. They found that the haemoglobin
of patients with sickle-cell anaemia has a different migration in electric fields to that
of normal haemoglobin, and hence the field of molecular disease was established.36
Moving-boundary electrophoresis was an extremely tedious way of separating
proteins, but it soon became apparent to several groups, most notably that of
Smith and Conley in the USA and Herman Lehmann in the UK, that it is
possible to separate proteins, at least in a crude kind of way, using filter-paper
electrophoresis.37 In the late 1950s Henry Kunkel, the immunologist, developed
starch-slab electrophoresis, which made it possible to identify and quantify the
minor haemoglobin components.38 Since one of these occurred at an elevated
level in the parents of patients with severe thalassaemia, it became possible to
identify the carrier state for at least some forms of this condition. Indeed, it was
this tedious and messy technique that was my entree to the thalassaemia field
while I was serving as a medical officer in the army in Malaya. Frank Vella, a
biochemist in Singapore, brought my attention to Kunkel’s paper and, because I
had a Ghurka child under my care with some features of thalassaemia, Frank and
I spent some time – literally covered from head to foot in starch – trying to develop
this technique. In the end we were able to prove that the child had thalassaemia.39
Just after I moved from Singapore to the USA in 1960, Oliver Smithies developed
starch-gel electrophoresis, which made it possible to identify all the minor
haemoglobin components.40 Roy Shooter and Ernie Huehns in London, and our
own group in Baltimore, started to apply this technique to haemoglobin analysis,
and it was an enormous help in the early days of both haemoglobin and
thalassaemia research. At the same time, Max Perutz was achieving remarkable
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success in defining the crystal structure of haemoglobin, and Vernon Ingram had
shown that the sickle mutation occurs in the β-globin chain. Vernon, together with
Tony Stretton and others, had also suggested that the thalassaemias might result
from a reduced rate of production of the α or β chains.41
When I returned to Baltimore for two years in 1962 I wanted to study the in
vitro production of haemoglobin, both in normal people and in individuals with
different forms of thalassaemia. I was able to label the chains in vitro and found
that there was unequal production in the different forms of thalassaemia, but I
could not get the system to be in any way quantitative, largely because there was
no good way of separating the globin chains. At about this time John Clegg, a
young postdoc who had been working with Neurath in Seattle, but had fallen out
with him because he did not like getting out of bed early in the morning for
journal clubs, arrived in Baltimore. John started to work on the synthesis of
insulin, but was having as little success as I was with globin. One day over tea while
discussing our mutual problems John suggested that we might try a separation
approach that he had used while doing his PhD in Cambridge. This worked and
we were able to quantify the rates of production of globin chains and therefore
accurately define the different forms of thalassaemia, and gain some insights into
what might be happening at the molecular level. This technique was also extremely
valuable for studying haemoglobin synthesis during fetal development, and when
we returned to Liverpool in the mid-1960s Bill Wood joined us to do work on a
PhD project that analysed haemoglobin at different stages of fetal development.
During this time we and others showed that there was a small amount of β-chain
production from about 15 weeks of development onwards, a finding which soon
led to the application of our globin-synthesis technique for prenatal diagnosis.42 I
am sure that Bernadette Modell will have more to say about this. 
Of course, in the 1960s and 1970s the nucleus was simply a black box, and all
we could do was to study cytoplasmic phenomena like globin-chain synthesis
and try to make some crude guesses about what might be happening at the DNA
level. With the advent of DNA–RNA hybridization we realized that a tool now
existed to probe to see if genes had been deleted, something that we were fairly
sure was happening in some forms of α thalassaemia. Knowing what we wanted
to do but not having a clue how to do it, we travelled to Glasgow to meet John
Paul to design an experiment whereby we would probe for the a globin genes in
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babies who had been stillborn with severe α thalassaemia. John set two young
scientists, Sergio Ottolenghi and Bob Williamson, to work on our material, and
this led to the first direct identification of a mutation in human beings.43 Soon
afterwards Southern blotting was developed and a little later DNA cloning and
sequencing, and we were able to apply these technologies to the molecular study
of thalassaemia.44 So by the early 1980s we had a good method for studying fetal
haemopoesis for prenatal diagnosis, most of the tools required for carrier
detection of the different thalassaemias, and were getting fairly close to the
molecular pathology of many of these conditions. Interestingly, this field was
developed by individuals of broad backgrounds, none of whom were clinical
geneticists in the sense that the term is used today. I suppose the field of blood-
group genetics developed in the same way, and probably many other areas of what
have become amalgamated into clinical genetics came initially from other
disciplines. I will stop there, I think. You can continue any of that if you want to.
Pembrey: Yes, I think it would be good to continue, because genetic testing is
identified with clinical genetic services, and it would be good to get some feel for
where all the strands came from. You were up in Liverpool and Cyril Clarke had
come in late from general medicine into medical genetics. There was the Galton
Laboratory and then there were the cytogenetic developments and it is important for
us to document where the main strands were. Was it mainly the Galton Laboratory
that led into the development of clinical genetic services, or was it John Fraser
Roberts and Cedric Carter at Great Ormond Street, with that very clinical end that
was the main channel? I think it was a coming together of a whole group of people. 
Dr David Tyrrell: There was one other strand, which was taught to me in the 1940s
as a medical student. That was blood transfusion and the blood grouping, and that
goes back to Landsteiner and the beginning of the century.45 Perhaps later I can tell
you how that involved me in infectious diseases, but it was a strand anyway.46
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Pembrey: The Clinical Genetics Society was formed in 1970,47 and their first
meeting was up in Edinburgh in October 1970. Before that time, there were
already services in existence.
Professor Ursula Mittwoch: Just a small point on scientific history. Paul Polani
mentioned sex chromatin, and this reminds us that cytogenetic testing began
before 1956. It began with the discovery by Barr and Bertram in Canada, in
1948 or 1949, of the nucleolar satellite that would distinguish the neurons of
male and female cats.48 Later, sex difference was found in other types of
nondividing cells, and also in humans. Females had a sex chromatin body or Barr
body, and males lacked it. I think the first patient examined was a true
hermaphrodite who also had Barr bodies.49 It was then shown that Klinefelter
syndrome patients had this Barr body, even though they were male, and Turner
syndrome patients lacked it. So with this information in mind, when
chromosome studies began, the early cytogeneticists were primed to look for
these patients, in particular Turner syndrome and Klinefelter syndrome, and the
rest is history.50
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Polani: Perhaps it’s worth remembering that the discovery of sex chromatin was
an accident. The reason why they were investigating neurons was neuron fatigue
of Canadian airmen in this country, which Barr was attached to as a medical
officer. In studying neuron fatigue they found a little satellite that was moving up
and down into the neurons and they thought that this was significant to neuron
fatigue. Then they discovered that some animals had this and other animals did
not have it, and luckily a technician had kept a record of the sex of the animal.51
Professor Malcolm Ferguson-Smith: It was Bertram who kept notes of the sex
of the cats and so it was good scientific practice that discovered it, rather than an
accident. Fortunately Paul, and to some extent Ursula, have made some of the
comments that I was going to make about the introduction to cytogenetics. I
would like to say that cytogeneticists have always been slaves to technology and
you will remember that the people who looked at chromosomes first in the 19th
century were looking at sections of gonads, and Hansemann and Flemming
came to the conclusion that there were about 24 chromosomes.52 A different
number wasn’t found until 1912, when a Belgian, de Winiwarter, looked at
gonads and found 47 in the testis and 48 in the ovary.53 He thought that sex
determination in humans was XO/XX, but in 1921, eight years later, Painter
discovered the Y chromosome in testis. So he added one to the 47 that
Winiwarter found and that came to 48. But in his paper in 1923, he said the
very best mitoses had 46 chromosomes.54 Then in 1932 I think people were
interested in the possibility of chromosome abnormalities in certain situations
and it was Waardenburg in 1932 who suggested that nondisjunction might
occur in Down’s syndrome (mongolism as it was called in those days).55
I want to go back to Ursula Mittwoch and to say that she, in 1952, looked at the
chromosomes in Down’s syndrome, well before Lejeune, and she looked very
carefully at diakineses.56 I hope she is going to say something about this and put
me right, because in her paper she counted 24 elements as diakineses and
probably, looking back on it, they might have been 23 bivalents and one
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univalent. Ursula, if you had had the opportunity of looking at a normal male –
it was difficult to get normal males to give up bits of their testes – you would
have discovered Down’s syndrome many years before Lejeune. Again, being
slaves of technology, the people before Tjio and Levan in 1956 had very poor
material to work with. It was the use of chromosome cell cultures and the
discovery that if you put the preparations by mistake into water instead of isotonic
solution, then the cells swelled up and separated the chromosomes and indeed
elongated the chromosomes artificially, and made them visible. Levan, of course,
contributed to cytogenetics by discovering in plants that colchicine could arrest
mitosis. So I think the impetus to study human chromosomes in the UK did
come from Barr and Bertram’s discovery. Although Paul hasn’t told us, he tried to
look at chromosomes in Turner syndrome in 1957, and I was trying to do it with
Klinefelter syndrome at the same time.56a But the preparations that I made were
absolutely terrible. You could make out that there were chromosomes there but
you couldn’t possibly count them. I was prompted to do this by the fact that we
found a patient with Klinefelter syndrome, a young man who was going into the
army, and was found to have small testicles. He came for testicular biopsy, and in
this testicular biopsy was a tubule full of spermatogenesis and sperm, and there were
sex vesicles with the XY in these primary spermatocytes. I rushed along to Professor
Pontecorvo and said, ‘Everybody’s saying these Klinefelters are sex-reversed females
but this man has a Y chromosome’. To cut a long story short, I was directed to
Charles Ford who had just been making bone marrow preparations.57 This would
be about 1956 or 1957. Charles didn’t know anything about Klinefelter syndrome,
but I told him about it and said, ‘Look we have lots of patients here,’ and he said,
‘Oh well, if you can get some bone marrow from these patients you can perhaps
count their chromosomes, I am working on the method but this is not quite ready
yet, but I will tell you when.’ So every time Mr Mack in Glasgow did a testicular
biopsy on a Klinefelter individual they woke up with a little hole in their sternum
from where I had taken a large chunk of bone marrow and these produced the
terrible preparations that we made. Charles Ford later managed to get a Klinefelter
sample from London and this was published in 1958 in Nature, in a paper
describing the bone marrow method.58 This Klinefelter patient had 46
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chromosomes and an XX karyotype, so this was the first XX male. This is not widely
known, and it is an important piece of history, and he felt that this confirmed that
these patients were sex-reversed females. One of his postdocs, Pat Jacobs, came to
work with Charles at the time, and she repeated this on several patients later and
found XXY. So these are little bits of anecdotes which took us on. 
I think that one of the most important milestones in cytogenetics, particularly in
relation to testing, was the discovery in 1960 by Moorhead and Hungerford of the
use of phytohaemagglutinin to stimulate lymphocytes into division.59 In a short-term
culture, in less than three days, it was possible to have a very nice looking
chromosome preparation from a peripheral blood sample. This technique was so
straightforward and it spread rapidly throughout the world, so that any pathology
department that read the paper could do it. This meant that the search was on to find
other disorders such as Down’s syndrome, and Klinefelter and Turner that might have
chromosomal syndromes. So a great deal of testing was done at that time. 
Then, of course, John Edwards, who is here, referred tissue from an autopsy of a baby
he had seen in Birmingham, and considered likely to have chromosomal
abnormalities, to Charles Ford and David Harnden. An extra chromosome 18 was
found, at first thought to be chromosome 17. This was before phytohaemagglutinin,
which allowed blood cultures to be used, had been discovered. 
Pembrey: So can I ask more widely, where were the cytogenetic tests being done
in 1960 in the sense that people would say that this is a test we need for the
clinical assessment of this child, or this person? 
Ferguson-Smith: At places like Harwell60 with Charles Ford and those colleagues
from the Galton Laboratory who worked with him, and at the MRC Unit in Oxford.
Pembrey: So they would receive clinical samples, would they?
Ferguson-Smith: They would indeed and, of course, at the Galton Laboratory,
Ursula can tell us more about that. The other places were largely departments of
pathology – I would say after 1960, all round the world, certainly at Johns
Hopkins. I had gone there in 1959 and started up a laboratory in its Department
of Medicine, which was probably the first diagnostic laboratory in the USA for
chromosome abnormalities. Then the obstetricians took it up, and then the
paediatricians. So, in fact, it was such an easy technology that many people
joined in, and the whole field exploded in a very satisfactory and productive way. 
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Zallen: What does it take to believe what you see? You said there had been
preparations, the very best preparations, in which there were 46 chromosomes,
and yet those weren’t taken seriously. Can you explain that? Or is there anyone
who knows why they were dismissed?
Ferguson-Smith: These were very difficult histopathological sections to look at.
Painter got his preparations from the testes of executed criminals in Texas and he
had to determine the number of chromosomes from serial sections. 
Pembrey: I am trying to go back to testing. John, were you testing, or involved
in doing clinical diagnostic tests, chromosomal tests in 1960? 
Professor John Edwards: Yes, I went to the Children’s Hospital of Philadelphia
in 1960, after establishing tissue culture in Oxford following help from Harwell.
At Philadelphia I learned the blood culture technique from Nowell and
Hungerford,61 and I established their chromosome laboratory. I returned to the
position I had held three years earlier in Birmingham with Professor McKeown
with a joint, if informal, appointment with Professor Hubble in Paediatrics, and
established the original chromosome laboratory in Birmingham. It was, I think,
the only one in England north of Harwell with Charles Ford in London, Penrose
at the Galton, and Polani and Hamerton at Guy’s. There were leading
laboratories established in Glasgow and Edinburgh. In Birmingham the flow of
material was limited by resources (one technician and a rather ancient
microscope), but at least there was no waiting list with reports within a week on
nuclear sexing on both buccal smears and blood, and a month on biopsy
material. I saw all cases before accepting, apart from buccal smears. 
Polani: At Guy’s we had established a research unit that had a dual track.
Research on the one side and then genetic service, and that was 1960 when we
were doing the first chromosomes.62 The work of Steele in the USA on detecting
chromosomes in amniotic cells was very important. [From the floor: 1966]. The
other important point was the discovery of chromosome translocations in
Down’s syndrome, which immediately raised the problem of being able to spot
familial mongolism,63 and that was important in a practical sense. Of course, the
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63 Professor Joy Delhanty wrote: ‘Familial mongolism due to translocations was first found at the
Galton Laboratory in 1960 by Joy Delhanty, then a PhD student of Lionel Penrose.’ Letter to Dr
Daphne Christie, 4 September 2002. See Polani et al. (1960); Carter et al. (1960).   
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forerunner to the chromosomes in amniotic cells was the work of Sachs on
amniotic nuclear sexing in Glasgow.64
Mittwoch: Just a brief mention back to the Galton laboratory. The testicular
biopsy of a Down’s syndrome patient that Malcolm has mentioned, this was a
task given to me by Penrose, and I wasn’t really satisfied with the preparation and
had no wish to publish it. But Penrose said, ‘Yes, you must because these Down’s
syndrome patients might be triploid’. I could see from the preparations that they
were not triploid, and so a page went into the journal that was still called Annals
of Eugenics in those days.65 So that was 1952. 
In 1961 Penrose collected material from aborted fetuses, from University College
Hospital, and Joy Delhanty found one of them to be triploid. I believe that this
was the first chromosome abnormality in an aborted fetus, of which there were
many more to come (see Figure 1).66
Professor Derek Roberts: You asked for places where chromosomes were being
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65 Professor Ursula Mittwoch wrote: ‘The name of the journal was changed to Annals of Human
Genetics in 1954.’ Letter to Dr Daphne Christie, 4 September 2002.
66 Penrose and Delhanty (1961); Delhanty et al. (1961); Carr (1967).
Figure 1:Triploid cells in a human embryo. Penrose and Delhanty (1961).
Photograph provided by Professor Joy Delhanty, 2003.
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examined in the early 1960s. I recall, and John Edwards will bear me out, that
Alan Stevenson had already set up a unit. When he moved from Northern
Ireland he came to Oxford, the MRC Population Genetics Unit, he had a
chromosome laboratory there that was doing service work, albeit on a small
scale. I remember it because the technician who did the work was George Clarke
and when I started my department in Newcastle, George Clarke came up to help
me set up the chromosome laboratory and order the apparatus.
Edwards: Can I just comment on Oxford with George Clarke in 1957? George
Clarke had been trained up in Glasgow and knew how to grow cells and wash
up glassware. Basically he had the techniques, which were very well established
in Glasgow, of cell growth and handling glassware – a major problem at that time
outside Glasgow, where tap water was pure and sterile. At that time it was quite
primitive, I had to go every Wednesday and chat up some farmer not to sell his
cock, because we were entirely dependent on fertile hens’ eggs, which were
extremely difficult to get.
That technique was developed by Lejeune in Paris, incubating bits from a skin
biopsy in clotted embryo extract in test-tubes with culture media and serum. In
1958, with limited equipment – he incubated samples by strapping test-tubes to
his body – he discovered the chromosomal abnormality in Down’s syndrome
(then termed mongolism): patients either had too few or too many
chromosomes – there were 47.67 Ford and Hamerton at Harwell, Tjio and Levan
at Lund, and Hsu at Yale had defined the correct number that year.68 At
Oxford I had great help from Ford and Harnden in learning their
nonphotographic techniques of analysis and referring difficult problems. These
included the first cases of 18q deficiency and what we then termed ‘mosaic’
and ‘partial’ mongolism.69
A point I wish to mention is Carr’s work in Canada on spontaneous abortions.70
He showed that about half had an extra autosome or missing sex chromosome.
If this early work, fully confirmed from numerous studies, had been appreciated,
affected sib-pair analysis would never have been established in the 1980s in place
of the sib-pair analysis, including unaffected controls, advanced by Penrose in
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69 Vollman (1969). 
70 Carr (1967).
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1935.70a It was clear that it is a dangerous business getting from conception to
birth for largely genetic reasons. 
Pembrey: We haven’t got any of the three key people with regard to
pharmacogenetics able to be here today, although they were invited, so we are
not going to have much on pharmacogenetics at the end of the session. So we
will have prenatal screening and prenatal testing after tea. One final word on
cytogenetics and we can come back to this at the end if necessary.
Ferguson-Smith: Marcus, we can’t leave cytogenetics without talking about
banding and about molecule cytogenetics, so I will try to do this very quickly.
Banding, of course, came about because Joe Gall and Mary Lou Pardue in the
USA were looking at and characterizing satellite DNA, the mouse satellite DNA
that was found in their DNA preparations separated by ultracentrifugation. They
hybridized preparations of satellite DNA to mouse chromosomes and found that
this hybridized to the paracentromeric regions of all the chromosomes. In order
to do this you had to denature the chromosomes and in some of these
preparations Giemsa-positive bands appeared especially near the centromere, and
this banding was developed further by others, including Seabright, Dutrillaux and
Adrian Sumner, to develop the R banding and trypsin banding, and various types
of banding that we now know, with which we can identify every individual
chromosome unambiguously. So this was a very major step that led to the further
identification and detection of even smaller chromosome aberrations.71
The next step was to try to develop the in situ work of Pardue and Gall. The first
thing that was done was to find the location of nucleolar ribosomal genes. Then
early attempts to find single-copy genes were unsuccessful until recombinant
technology came to the fore, when it was possible to clone sequences in plasmids
and to get larger amounts of DNA material to test. That was difficult, it took a
long time and those of us struggling with tritium-labelled DNA probes had to
wait for three weeks and had to count lots of silver grains – it was a bit of a pain
in the neck. So we were all very pleased, as Sue Malcolm will testify (she was
there at the very beginning of all this), and we were very glad when fluorescent
probes came along. They came along probably round about 1986 or 1987 and
it was possible to biotinylate DNA probes or couple them with digoxigenin and
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John Edwards wrote: ‘The presence of control – the discordant sib pairs, is implicit in this article.
Penrose introduced the hyphenated term “sib-pairs” in 1937.’ E-mail  to Dr Daphne Christie, 4
September 2003. See also page 27.
71 See, for example, Seabright (1971); Sumner (1982).
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then eventually to get direct labelling of nucleotides with fluorescent dyes. This
led to multicolour FISH,72 to the centromeric probes used for aneuploidy
detection, to test for trisomies not just in cultured cells, but also in interphase
nuclei, and that’s been a very important development, which is much exploited
nowadays. Then with chromosome sorting and with reverse painting, whole-
chromosome paints could be made which would colour (hybridize) the complete
chromosome along its length. From that came the complete multicolour FISH,
where every chromosome in the human karyotype was given a different colour
on one hybridization and could be used to look for rearrangements. In 1997,
probe sets were being developed which defined the telomeres of chromosomes
and that was very important, because they could be used to identify cryptic
rearrangements at the ends of the chromosomes. 
Finally, a word about how, if and when DNA arrays are going to take over from the
FISH work. It’s possible, of course, to put genomic DNAs in microarrays on slides
and use the comparative genome hybridization technique to identify copy numbers
of various sequences throughout the chromosome. A very nice recent application
from Nottingham (just to bring us right up to date) has been a technique called
MAPH [multiplex amplifiable probe hybridization], in which sequences at the
telomeric ends of the chromosomes are distinguished by being different in size.73 By
amplifying these probes you can get a whole pattern of sequences on a gel, which
can be scanned and tested for copy number. This promised to be a useful technique
to determine unbalanced chromosome aberrations occurring at the ends of
chromosomes. That takes us right up to the present day. I believe cytogenetics and
chromosome analysis have been at the very centre of genetics, and they will continue
to be so for a number of generations to come.
Pembrey: Thank you. We are going to move on to linkage now, and, if we could,
try to tease out a little more of the individual contribution of people, rather than
just rather politely describe the general trends. If you were involved in a
particular technique and so on, and can remember anecdotally key successes or
key failures, then that helps as well for the historians. I want to move on to
linkage and DNA testing. We put the two together because again we need to
focus on how we went from the establishment of the principles and ideas of
linkage in the 1930s to the actual application of linked markers, whether they be
blood groups or, subsequently, DNA markers and so on, in genetic testing in
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Letter to Dr Daphne Christie, 12 August 2002. See Glassman (1998). 
73 Hollox et al. (2002).
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families with genetic disorders. I am just reminded of John Fraser Roberts’ book
of 1940 where he talks about the practical value of chromosome maps.74 He says
that at the present time all that can be said in relation to a dominant condition
is that, on the average, half the offspring of the affected persons will themselves
be affected. If however the manifestation occurs late in life, as in Huntington’s
disease – Huntington’s chorea as you called it then – there is a problem because
a daughter, for example, wouldn’t know if she was affected before reproducing.
John’s book goes on to say how valuable it would be to have a marker with a
cross-over value of 10 per cent, you could at least say there was a 10 per cent or
a 90 per cent chance and so on. So the theoretical idea that linkage could be used
to help families, for genetic prediction, was clearly established early on, but how
did it happen in practice? Could we just start perhaps with the non-DNA, the
earlier markers and so on, perhaps Patricia Tippett, or perhaps John, you could
tell us a bit about the blood groups and the theoretical background, using genetic
linkage in a predictive sort of way?
Dr Patricia Tippett: The Americans must have been the first to appreciate that
blood-group antigens were good markers, because they are well-expressed and red
blood cell samples are easy to get. In New York they deliberately, with two systems
(MN, P), injected rabbits and then absorbed the rabbit serum with other bloods to
make reagents to detect differences other than ABO. Dr Race always said that it was
Sir Ronald Fisher who anticipated the use of blood groups as chromosome markers,
for mapping chromosomes. When Fisher was the Galton Professor in 1935 he started
a department to do blood groups. There were only three blood groups identified at
this time, and ABO was the common one. He started this as the Galton Laboratory
Serum Department, which then moved to Cambridge during the war. It was not
until the finding of Rhesus (Rh) in 1939/194075 and the clinical significance of this
antigen, and the development of techniques that could detect clinically significant
antibodies that the whole lot blossomed. In the 1940s and 1950s, red blood cell
groups were the ones that were used as markers and certainly at the MRC Blood
Group Unit we used to test family members of people with various diseases that
colleagues sent in to us, such as Huntington’s. Unfortunately, we never found any
linkage, but the first four, I think, autosomal linkages found involved a blood group.
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Marcus Pembrey: What about the ABO and nail-patella syndrome?
Tippett: Yes, that was one of them. Also, I think, Rh and elliptocytosis.
Pembrey: That discovery was made by Renwick and Sylvia Lawler. 
Ferguson-Smith: I think Jan Mohr was the first with the Lutheran blood group
and secretor status.76
Professor Sue Povey: I wonder how many of the early workers had the foresight
to think that this would be really useful or whether they were motivated mostly out
of academic curiosity, which is something that is less encouraged in these days. I
remember that in Race and Sanger’s book, the early one, there is one of the best
easy explanations of how to do linkage. They say we wouldn’t like blood groupers
not to have the pleasure of recognizing a linkage, should they come across one.77
Pembrey: You felt that there wasn’t much of a drive to use this for genetic prediction,
it was really still trying to find, to publish linkages. After all, there were so few
linkages and it was even more difficult to find their chromosomal localization.
Povey: I suppose at the time that Patricia is talking about, when there were so few
blood groups, the chance of finding a positive linkage with the disease was very low.
Tippett: Yes, it was very small. I think Fisher had anticipated finding linkages
because in a later paper on blood groups, Race and Sanger say something about
how he would have enjoyed the sort of explosion of blood groups and the
increased hope of mapping. We were very naive in our expectations, even when
we found Xg78 on the X chromosome, which was already known to have many
markers. At first we said that we would only be able to map the X chromosome,
but we were unfortunate because only three loci were within measurable
distance. However, we learned a lot about other things, especially in
understanding the mechanisms of sex-chromosome aneuploidy.
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linkages from the Galton Laboratory by Sylvia Lawler and Jim Renwick and colleagues. These were
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77 Race and Sanger (1950).
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Polani: What you said about John Fraser Roberts, he certainly recognized the
usefulness, the clinical usefulness, of the application of linkage, although he
worked mostly on association. I think probably he was, I don’t know, he was one
of the first, or maybe we should look at what Crow was thinking of.
Pembrey: I don’t think we can leave the early period without at least talking
about Julia Bell and Haldane, with the linkage between colour-blindness and
haemophilia.79 After all, that was potentially used in 1936, 1937. Does anybody
know whether that was used clinically? That linkage?
Edwards: The concept was. It’s a concept that has dominated all future use, but
I don’t think it was used at the time.
Professor Naomi Pfeffer: Could you explain what you mean by ‘used clinically’?
Pembrey: Being used as a test to predict the genetic status of a family member
who didn’t know their genetic status. That’s really it. The ABO and nail-patella
linkage I guess could have been used in informative families for that purpose,
although it would be fairly obvious, they wouldn’t want to do it. 
Zallen: I was looking some years ago in the Rockefeller Foundation archives at the logs
of the officers who travelled around the world trying to find suitable and eminent
scientists to fund. They were visiting R A Fisher and he was explaining something very
important, what work he wanted to do. This was in 1939, and he was talking about
linkage. He said, ‘Suppose you see a family in which red hair always goes with
madness, then you could use the red hair as the marker for predicting future problems
of an individual’. So he very clearly had that on the agenda in 1935. 
Tippett: The Galton Laboratory Serum Unit was set up with a Rockefeller grant
administered by the MRC.80
Edwards: In 1912 when eugenics was a highly respectable word – it was respectable
until 1930 in most of Europe – Fisher was an active member of the Cambridge
Eugenics Society as a postgraduate, an astrophysicist. He gave a paper and specifically
pointed out, what was later pointed out by Haldane and later still by Fraser Roberts,
I think, on the inferences you could get by being able to detect ‘factors’, as he called
them then. Historically the linkage followed from the work on the white-eyed fly in
1912 and Morgan’s book.81 In 1918, they had mapped 40 loci. In 1918 the term
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‘linkage inequality’ (and what is now called ‘linkage disequilibrium’), was put forward
in Ann Arbor by Robbins.82 Following that was Fisher’s book in 1930 when he wrote
on the potential for linkage equilibrium,83 which is a very important concept. In the
HLA [human leukocyte antigen] system, there are sets of alleles that coexist with
advantage, and he put that forward as a possible cause 30 years before HLA typing
was developed. Lewontin84 never mentioned Fisher as he thought he was upper class:
there was no reference to what Fisher had called linkage equilibrium and Robbins’
linkage inequality. This is why I introduced the term ‘allelic association’ as the
observation from which all these things arise. 
In 1931, Bernstein in Geissen, Germany, advanced the concept of using two
generations rather than three85 and I am glad to say that with effect from last
Saturday I was able to get his original document, found in a basement in
Munich, on to my website.86 I would welcome help on the translations, but the
original German is very original. He was pushed out for being Jewish – from a
very distinguished Jewish family – and didn’t do a great deal after going to the
USA in 1930. Following the demonstration that you could do linkage in two
generations, and it was very difficult because of course most of the blood groups
used in linkage were not codominant. Some had a very difficult kind of
dominance, as in the ABO system. So he went into this and pointed out in his
paper that as humans had 24 chromosomes, they were probably tetraploid or
otherwise polyploid, which would make life easier. He distinguished association
from linkage very clearly, particularly in usage on cows, and then this was taken
up by Haldane and Hogben. 
Four years later Penrose pointed out you didn’t need two generations, one
generation sufficed, and you didn’t need parents, because although they were
helpful, they were not cost effective. The important point he made was that
without linkage you have discordant signs, the phenotype and a discordant
genotype, and you just do a very simple test. This is the basis of the sib-pair
analysis of Penrose:87 which has been completely ignored by all later authors. It
is obviously a very powerful method, and Fisher gave it tremendous support.
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Fisher also contributed to the first paper; of his eight children several had red or
reddish hair. I don’t think I wish to say any more on this, except that by 1935
the basic procedures for linkage analysis were very well established, with a
succinct and sufficient vocabulary. However, efficient analysis had to wait ten
years for the likelihood approach of Haldane and Smith, twenty for Morton’s
tabulation of lod scores, thirty for its transfer to computers and almost another
ten for Ott’s development of a fully generalized linkage programme.88
Pembrey: Very helpful. We now want to move to the actual application of that.
I know John Woodrow with Andrew Cudworth was involved in some early
analysis in diabetes.
Professor John Woodrow: John Edwards will be pleased to know that I have in
my hand a photocopy of the Lionel Penrose paper on linkage to which he
referred.89 In Liverpool in the 1950s Cyril Clarke, like nearly all those who were
associated with him in becoming involved in medical genetics, was a practising
physician and was largely self-taught in genetics. Stimulated by Philip
Sheppard,90 whose mentor in Oxford had been E B Ford (the ecological
geneticist), a research study was initiated to look for possible associations
between blood groups and disease. (It is a remarkable fact that the possibility of
a relationship between blood groups and disease was being investigated at the
Mayo Clinic in 1917, before the ABO terminology was introduced.)91 In spite of
much work in Liverpool and elsewhere and some interesting findings in respect
of blood group, secretor status and peptic ulcer, few notable additions to our
knowledge of disease pathogenesis emerged.92
At that time genetic linkage and population association were quite separate
things. If one were to find genetic linkage in family studies (and there were very
few examples of this in man) one would not expect to find population
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90 Professor John Woodrow wrote: ‘Professor P M Sheppard FRS came to Liverpool from Oxford in
1956 and was Head of the Department of Genetics from 1959 until his death in 1976.’ Letter to Dr
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92 Professor John Woodrow wrote: ‘The involvement with blood groups and disease led to an interest
in Rh haemolytic disease of the newborn, and to the experimental and clinical studies whose success
led in turn to a practical method of preventing the disease.’ Letter to Dr Daphne Christie, 14 October
2002. See Christie and Tansey (2004b).
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association. It is of interest that Cyril Clarke and Philip Sheppard, working in a
totally different field – the genetics of mimicry in Papilio memnon – showed that
this was determined by several tightly linked genes that were not in linkage
equilibrium.93 The term ‘supergene’ after Darlington and Mather was used. The
discovery of the HLA polymorphism was naturally of great interest to us and also
showed evidence of linkage disequilibrium. Thus, any disease susceptibility genes
in the vicinity of the HLA loci on chromosome 6 might thus be expected to
show both linkage and population association. As a rheumatologist I was able to
take part in studies that showed strong HLA associations with several rheumatic
diseases and in the case of the HLA B27-associated disorders, typing for B27 was
of direct use in the clinic.94
Andrew Cudworth95 and I decided to investigate the possibility that there might
be HLA-linked genes involved in the genetics of insulin-dependent diabetes
mellitus (IDDM). We first did a population association study, and this showed
an association with HLA B8 and W15. I was aware of Penrose’s paper, which was
published in the Annals of Eugenics in 1935.96 His introductory sentence reads:
‘The methods, originally devised by Bernstein and recently improved by Hogben
and Haldane, which can be used for detecting and measuring linkage, necessitate
the identification of parental genotype.’ He then goes on to describe the
advantages of studying pairs of sibs. (Penrose also suggested later that in
population association studies, healthy sibs could be used as controls in order to
avoid the problem of stratification.) One problem with linkage studies in IDDM
is that there is an appreciable chance that unaffected sibs would become affected
subsequently, and we decided to study affected sibs only. Mattiuz had shown that
normally there is random zygotic assortment of HLA haplotypes in families. We
therefore tested the null hypothesis that this would also apply to families of
diabetic sibs. If sharing of parental haplotypes was significantly greater in these
sibs than expected, this would suggest the presence of an HLA-linked
susceptibility genes(s) for IDDM. 
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95 Professor John Woodrow wrote: ‘Andrew Cudworth FRCP was Lecturer in the Department of
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We reported on 17 families, 15 sib pairs and two with three affected sibs.97 There
was a marked excess of sharing of parental haplotypes and this supported the
population association findings in indicating the site of what is probably the
major genetic factor in susceptibility to IDDM. The affected sib-pair approach
has been applied to the genetic analysis of many more or less common disorders,
using an increasing array of polymorphic markers and more sophisticated
methods of analysis.98 It is not as successful where disease susceptibility genes of
weak effect are involved. Population association studies are still valuable and the
transmission disequilibrium test is another test of association that is often used.99
Pembrey: That’s a good example of HLA being used in research to establish
linkage. On the clinical side, I do think that HLA linkage was used for genetic
prediction. I certainly used it, I can describe a family in the early 1980s, where I
used it, where they had congenital adrenal hyperplasia, 21-hydroxylase
deficiency. Rodney, did you use HLA for genetic counselling prediction in 21-
hydroxylase deficiency in congenital adrenal hyperplasia in Manchester?
Professor Rodney Harris: Not really, we used the biochemistry more. I don’t
know whether you want me to talk about what I thought I was going to talk about.
Woodrow: To put the IDDM story in the context of the general topic of this
meeting, it is known that possessing the HLA DQ8/DQ2 genotype is associated
with a high risk of developing IDDM. If in addition there are present two or
three of the main autoantibodies found in patients with IDDM, the risk is even
higher. It has been known for some time that progressive destruction of
pancreatic islet cells occurs for some years prior to the appearance of clinical
symptoms. This has suggested the possibility of carrying out some form of
immunomodulation to protect the islet cells in those identified as being
genetically susceptible – for example, sibs of probands – thus preventing the
onset of disease. Clinical trials along these lines are currently in progress. 
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Pembrey: I can certainly describe one instance when we used HLA as a marker
for genetic prediction of other family members. This was a family from the
Mediterranean, they were first cousins, they were a Muslim family, and a child
had been born with ambiguous genitalia, and shown to be 21-hydroxylase
deficient. And then there was a comparable consanguineous marriage, that is
another sister had married another one of the brothers and had only had one
child who was well, and they were worried about their recurrence risk. Then
there was another pairing, comparable consanguineous marriage, where they
were planning to get married, but people were worried about this genetic
condition, and we decided to use linkage. It was published in the Archives of
Diseases of Childhood, in the early 1980s, about 1982, perhaps.100 We certainly
used HLA as a means of demonstrating that the family that had already married
and had a child, they weren’t carriers either of them, or at very low risk of, and
therefore could carry on without any concern, and likewise the couple who
wanted to get married also got the good news that they could get married. So
there were sporadic examples of using linked markers to disease loci for genetic
prediction in families.
Zallen: How about the secretor gene and myotonic muscular dystrophy?101
Edwards: We had hoped Peter Harper would be here; he had to bow out at the
last minute. Anyway, with Jack Insley we had a suitable case in Birmingham,
and he came down to demonstrate myotonic signs in the offending grandparent
by hitting very hard using the small American patella hammer he had brought
from Cardiff.
Pembrey: So this was prenatal diagnosis? Ours wasn’t.
Edwards: Yes, prenatal diagnosis. It was sorted out by somebody with a very
large clinical experience of this condition, who realized you had to use these
small American hammers which are very good for that particular test. I am sure
that it was done by all the right people. I forget the exact result, but it was
published and was almost certainly the first case.102 The credit goes to the secretor
expert, Dr Tippett, who did the difficult tests in London.
Tippett: We were doing a lot of tests for colleagues studying these things.103
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Edwards: Could I mention a single point before we go on? The HLA association
with the adrenal problem – that was picked up entirely by association studies,
and not by family studies.
Pembrey: So there was a relatively limited use of non-DNA markers for
prediction within families, a test as it were, until the DNA side came on. I don’t
know who to ask to get started, certainly haemoglobinopathies were using DNA
markers, and Sue Malcolm was very involved in the early service work on this.
Weatherall: Although it had been suggested by J B S Haldane, John Edwards
and Walter Bodmer, I suspect that the first intimation that one could use DNA
markers clinically came from a talk that we heard in a monastery in Crete in the
late 1970s. It was something of a difficult talk because the speaker, Yuet Wei
Kan, had left all his slides on the aeroplane and had to ad lib as he went along.
However, it turned out that he had been looking at the DNA of normal people
and those with sickle-cell anaemia using the restriction enzyme Hpa I. He had
found that the β-globin gene of normal individuals is located on a fragment
approximately 7.6kb, whereas using the same enzyme it was found that the 
β-globin gene of patients with sickle-cell anaemia was on a larger DNA
fragment, approximately 13kb. It appeared, therefore, that the sickle mutation
was on a chromosome that also carried a polymorphism of DNA outside the
coding area for the β chain, and further studies showed that it was a very strong
association. Since the sickle-cell gene had come under strong selection, the Hpa
I polymorphism had hitchhiked along with it. Shortly afterwards Y W Kan and
Andrees Dozy used this linkage for prenatal diagnosis of sickle-cell disease.104
Later a large number of polymorphisms were found to be in linkage
disequilibrium for the different forms of thalassaemia and again this approach
was used for prenatal diagnosis. Although this approach to prenatal detection of
the haemoglobin disorders did not last long, since it soon became possible to
identify the mutations directly, it was an important step forward and further
consolidated the idea that one might be able to use polymorphisms of this type
to search for genes of unknown function associated with disease.
Professor Sue Malcolm: As David has taught us, practically anything worth
knowing you could learn from the globin gene, so as well as Y W Kan’s
announcement in Crete, Alec Jeffreys was looking at variation around the globin
gene in general, not specifically in haemoglobinopathies. He published the paper
in Cell that showed that there were quite high frequencies of RFLPs [restriction
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fragment length polymorphisms] all around.105 That was when perhaps we made
the jump from it being something specific to a gene, with some association, I
should say, with coming out of the Kan thing, to the idea that these could be
markers at quite high frequencies, used in general. From then it moved on very
rapidly, still using RFLPs, so a number of groups were using this to map genes
in a systematic genome-wide method. Lou Kunkel was one example also Jim
Gusella, Bob Williamson and Peter Harper, and their various students in this
country. I would say that the whole thing was given quite a boost by the fact that
Gusella managed to find a linkage for Huntington’s on probe number 8 and
usually it is about probe 308, and I think if that had been the experience earlier
on, people might have been a lot less keen to pursue it, whereas Gusella’s success
made people think it was all going to be rather straightforward. Well, in
Duchenne’s dystrophy, of course, there was a chromosome hint as well, although
Bob Williamson went on record as saying that he thought it was rather a
nuisance that there was a chromosome hint, because he wanted proof that you
could do it without the chromosomes. But the chromosome hint there, which
was X autosome translocations in females, did indeed point to exactly the right
position for using the markers,106 and, as I said, Kunkel’s group used that and
then went on from that to the positional cloning.
Povey: I just wanted to add a memory about the finding of the linkage to the
chromosome 4 for Huntington’s chorea. There was a very big meeting, one of the
human gene mapping meetings, I think it was Los Angeles, and there were
numerous posters, but the most exciting one was scrawled on a white board, as
you went in, which was ‘Huntington’s is on chromosome 4’, and it was the
linkage, it was just a two-sentence poster, and that’s definitely the scientific fact
that most people remembered from that meeting.
Pembrey: So we have these linkages being established, but in parallel there were
suggestions that genetic testing, using RFLPs and so on, might contribute
towards genetic counselling. There was John Old in Oxford on
haemoglobinopathies, and then there were three centres: ours at Great Ormond
Street/Institute of Child Health, Manchester and Cardiff. The Department of
Health [DoH] in 1984–85 funded us as a Special Medical Development,  I think
it was to try to introduce, to assess, these approaches in genetic counselling. Also,
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there were studies going on in Glasgow, Cambridge and Guy’s. It was just that
the three DoH centres tried to look at some of the practicalities of getting these
services coordinated. Are there any particular points that people want to make
about those early days, particular triumphs or errors that were made?
Edwards: I would like to draw attention to the very significant paper by Dick
Lindenbaum, who picked up a translocation in a girl with typical Duchenne.107
This was a very significant paper, I think, and led to Lindenbaum and his
colleagues, including myself, examining as many girls and women with
Duchenne, or its milder variant (Becker’s syndrome), as possible and, most
already known to have translocations, and making sure samples were freely
available to anyone competent to study them, especially Professor Southern in
Edinburgh and Dr Worton in Toronto. Lindenbaum was very clear in his paper
where the locus was, why it was manifest in women, and the implications for
future research.107a Since then there have been several hoards of X-autosomal
translocations that have been picked up and which have pinpointed a locus with
great efficiency and precision in several disorders. 
Malcolm: I don’t know whether it’s worth recording that around that time, when
people realized that you could use markers throughout the genome, was perhaps
one of the first examples of the commercial involvement. One of the first total
maps was through a company called something like Collaborative Research with
Helen Donis Keller, so that was the first time when probes were not available, and
somewhat secretive and not all the full details were published, and that hadn’t been
the case up until then. Clones and things had been exchanged fairly freely I think.
Pembrey: Peter Pearson was a good example of somebody who handed out all
his probes, and he was very free and easy wasn’t he? You just rang up, you asked
and you got them.
Weatherall: Another interesting development around that time was the
recognition that hypervariable regions may be extremely useful diagnostic DNA
markers. One of the first to be properly characterized followed the work of a young
PhD student of ours, Steve Goodbourne, in a region that was particularly close to
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the α-globin genes. While this work was being done another young postdoc, Steve
Reeders, was working with us, attempting to find a linkage for polycystic kidney
disease. When he added the markers for the α-globin hypervariable region to his
study he obtained a very tight linkage, thereby pinpointing the gene for polycystic
kidney disease close to the α-globin genes.108 Later, collaborative work with the
group in Cardiff on a patient who had both polycystic kidney disease and tuberous
sclerosis, together with an appropriate deletion in the right region, led to the
discovery of the genes for both these conditions. 
Pembrey: Can I just talk about that family with the two diseases, because I was
involved in running MSc courses in Portugal, in Oporto, during the early 1980s?
When I was out there one of the geneticists there, whose name escapes me at the
present time [Heloisa Santos], showed me this family and said look at that isn’t
that fascinating, you know, what sort of research we can do in that. I said I think
it’s just a coincidence, you won’t get anything out of that. She then triumphantly
sent me a copy of the paper with the group from Cardiff, who had picked up on
it rather more sensibly, and this was a few years later.109 So that was certainly a
trick that I missed. [From the floor: And you were properly trained as well.]
Anything else on the linkage side? 
Ferguson-Smith: I would like to emphasize how excited we all were about how
quickly we could transfer the information that we got from our colleagues about
linkage to our patients. It was in the early 1980s, which is really when it all
started, and of course, with commercialization, as Sue has said, it’s become a little
slower since – but it was a very exciting time.
Zallen: I have a question. I have always wondered about the 1979 paper by
Solomon and Bodmer,110 which talks about the usefulness of linkage markers
throughout the genome. The 1980 paper by Botstein and colleagues111 is the one
that is always cited in the literature, the historical literature, as being the origin
of that idea. Is there any explanation for that?
Weatherall: He will be too modest to say, but I think there was one that set out
the whole thing a bit before Bodmer, and that was a guy called Edwards who is
sitting over in the corner.
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Pembrey: During this phase of trying to get linkage with diseases, because we
could translate the findings so rapidly into service for families, the lay organizations
got quite involved. I don’t know if there’s anybody here from LINK,111a but I think
it’s worth recalling an early 1988 neurofibromatosis meeting. It was a meeting that
Bruce Ponder was involved in – I wasn’t involved in neurofibromatosis-linkage
studies at all – and I know that John Edwards was there, and a number of others.
A lot of Americans had come over, and at that time there was a lot of linkage work
being done on neurofibromatosis 1, but there was no pooling of the negative data.
So I was asked, as someone who was not working on it, to take all the relevant
Americans and other workers into a room after the dinner and to get them to agree
to pool all their data for exclusion mapping. Mark Skolnick was there, certainly,
and after a bit of negotiation they eventually agreed to do this. Somebody took a
taxi to get your [John Edwards’] exclusion map programme, you weren’t there, but
I know somebody had to go to Oxford in the night anyway.
Edwards: I was there, and I collected all the data, excepting from Boston. I went
to Oxford because I had a computer there and I was busy that afternoon with a
clinic, so I sent a taxi with the results. It was about 30 miles, just by Heathrow
where they held these meetings [the Runnymede Hotel]. It was interesting, because
you very cleverly got everybody, with one exception, to let me have the data.
Pembrey: Yes, that was the plan, they were trapped. 
Edwards: One group from Boston refused, they never gave it, but they used it
afterwards, when they had everybody’s data. This was very fortunate, because the
person who provided a probe to Boston was in Iowa, and was very upset at being
left out. But in fact they had made a mistake with it. So if we had used the data
that they refused to give, we wouldn’t have found any linkage. [Laughter]
Pembrey: So what actually happened, which was very interesting for the lay
organization that ran this, they said (and they, of course, had the clout), look you
must all pool your data. We got people to pool the data, fortunately without the
erroneous data, and it went from not knowing where it was to only two places,
chromosome 17 and chromosome 10 or 11 I think it was, I am not quite sure.
It went from having no published clear information, to localizing it to one of two
chromosomes, and a little bit later the Boston group published, showing it was
on 17, and they had said that they didn’t know where it was. So I was very
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pleased that everybody had shared all this data, but in fact they held back, and
it turned out that they did have high suspicion that it was there. But you had
shown with your exclusion map, without their support, that it was either there
or in one other chromosome. I think that was a high spot in those early days also,
with the lay organizations being involved. 
Professor Charles Rodeck: I feel I should mention haemophilia, partly because
it’s a genetic disease not seen by geneticists because the patients are treated by
haematologists, and partly because Reuben Mibashan, my colleague in
haematology at King’s College Hospital, sadly died recently. He very rapidly
moved into linkage analysis, having initially developed a blood assay for prenatal
diagnosis on fetal blood.112 He enabled first-trimester fetal diagnosis and that
then spread quite rapidly. Certainly the patient association, The Haemophilia
Society, were very much behind that and in favour of it.113
Pembrey: Yes, the background to that first clinically used probe, DX 13, was that it
came from Kay Davies’s library, and I think her library paper was 1981.114 The
collaboration with Kay was crucial in providing the DX 13 probe. I was convinced,
if you could see fragile X down the microscope, it would be dead easy to see it at the
DNA level. That probe was being used for studies of fragile X and Robin Winter
suggested that we also look at haemophilia, and Ted Tuddenham had some families
at the Royal Free and lo and behold, it was strongly linked.115 So, in fact, that was a
very rapid move from biochemical- or coagulation-level prenatal diagnosis with all its
hazards and errors, to using a pretty closely linked probe. Then, of course, the gene-
specific RFLP came in very soon afterwards and that was in 1984, I think. Perhaps
we could move on now from linkage and DNA diagnosis to consider biochemical
genetics, because that is certainly one of the big three areas in genetic testing.
Malcolm: I think you should mention that polymerase chain reaction [PCR]. All
the things that we have said so far were done before PCR, and when that [PCR]
came in it immediately transformed everything: the speed; the fact that you
could use it for microsatellites; and the fact that you could then use it for
sequencing the actual genes, because the genes were becoming available at the
time of linkage, but you couldn’t use them, because it was a whole PhD project
to find a mutation. So from then on, it was all different.
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Pembrey: No, I think that’s a very good point, and I know when we come to
pre-implantation genetic diagnosis, there are some great stories on the PCR side.
Weatherall: It is a shame when talking about the British end of these
developments, not to remember Ted Tuddenham’s contribution in work directed
at finding the factor VIII gene. Ted purified some human factor VIII, not
completely but enough to obtain sufficient amino-acid sequence to construct a
gene probe.116 Of course an American company went on and found the gene, but
without Tuddenham’s sequence it would have been extremely difficult. I often
think that this achievement is overlooked. 
Pembrey: That’s a very important point. So perhaps we could just talk a little bit
now about the biochemical side. Before the molecular DNA diagnostic side, you
had cytogenetics and you had biochemistry, our main means of genetic testing.
I just wondered, Elisabeth, whether you wanted to say a bit from the Institute of
Child Health lab where Des Patrick played such an important role.
Mrs Elisabeth Young: I don’t think we can really start talking about biochemical
genetics, unless we go right back to the beginning of the 20th century, when Sir
Archibald Garrod introduced the concept of an ‘inborn error of metabolism’ and
the idea that enzymes are responsible for carrying out specific biochemical
processes.117 It’s in the last 25 to 30 years of the 20th century, that we have seen
enormous advances in the understanding of the abnormal biochemistry
underlying inherited metabolic disease. The key to this expansion of knowledge
has been the development of very sensitive techniques for the reliable detection
of the biochemical defect at the metabolite, protein or enzyme level, and more
recently, as we have been discussing, at the DNA level. More than 5000 human
disorders are caused by a single human gene mutation, and in most of these
metabolism must be affected at some stage of development. However, even now,
a century after Garrod first reported his patients with alkaptonuria, only in about
a tenth of metabolic disorders has the primary defect been established. 
So how did we go about diagnosing biochemical disorders and the testing of
families? In the early part of the century the specific diagnosis was often made by
the detection of the abnormal metabolite or gross amounts of normal metabolite
in urine. Sometimes this was a very simple procedure, and as we know they
would taste the urine, for example, for sugar (I think that would be against
health and safety regulations these days!). They could smell the urine of patients!
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Some emitted an unmistakable odour, for example maple syrup in maple syrup
urine disease. But in the laboratory it was the chemists who were helping with
the diagnosis; they were performing laborious and painstaking analyses of these
metabolites in the urine and in post-mortem material from spleen, liver, brain
and so on. It was these metabolites extracted from the liver and urine that we
subsequently came to use as natural substrates for the enzyme analysis. You
couldn’t ring up Sigma as we do these days and get the substrates sent by post
overnight. Obviously as with cytogenetics and DNA technology, there have been
enormous advances in biochemical technology. For example, we have moved on
now to mass spectrometry from paper chromatography. With mass spectrometry
we are able to analyse highly complex metabolites, and the structures of many
compounds have gradually been elucidated. 
We must not underestimate the contribution made by the histologists and the
histochemists to our understanding of pathology of these diseases, and helping us
with the diagnosis and genetic testing of children and families. Moving from light
to electron microscopy gave us a completely new dimension on the effect of
metabolites on the cell, and to this day, in disorders such as Batten’s disease, we
are still dependent on the histologists for the diagnosis of the variant subtypes. 
It was in the mid-1960s that the enzymic diagnosis for many of the metabolic
disorders really took off. Previously we required a biopsy of liver or the affected
organ, sometimes brain, but Des Patrick, as Marcus mentioned, showed that
spleen from patients with Gaucher disease was deficient in an enzyme called 
β-glucosidase. Des made an enormous contribution to the diagnosis of the
lysosomal storage diseases in particular, by demonstrating that the sensitivity of the
β-glucosidase assay could be increased at least ten-fold by the use of a synthetic
colorimetric substrate.118 Leaback and Walker at the Institute of Orthopaedics at
Stanmore and other workers synthesized a series of fluorogenic substrates that
increased the sensitivity a further 100-fold. So during the 1970s, by using these
substrates, the specific enzyme defect in most of the lysosomal storage disorders
was elucidated and now it became possible to make the diagnosis on a blood
sample, whereas before, as I said, we needed a liver, brain or spleen biopsy. 
In the 1960s cell-culture techniques moved from a research environment into a
routine laboratory and cultured fibroblasts were also used for diagnosis. In
addition we found that assays made in cultured fibroblasts could generally be
extended to cultured amniotic cells, which opened up the whole field of prenatal
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diagnosis of metabolic diseases. A pre-requisite for prenatal diagnosis is an
accurate biochemical diagnosis in the index case, and we now know that similar
clinical presentations may result from entirely different enzyme deficiencies. In
addition the relevant enzyme could now easily be assayed in the parents. We also
found that in some of the lysosomal storage disorders a few clinically normal
parents had as low an enzymic activity as their affected children. They are said to
have a pseudodeficiency of the enzyme. For reliable prenatal diagnosis we had to
have accurate methods to be able to distinguish an affected fetus from a clinically
normal fetus, irrespective of it being a heterozygote, or a homozygous normal.
The measurement of the relevant metabolite in amniotic fluid supernatant has
proved to be a reliable means of prenatal diagnosis in some disorders, but
generally amniotic cells had to be cultured for enzyme assay. 
When prenatal testing for a metabolic disorder was first offered in the 1960s and
70s, a diagnosis was not available until approximately 20 weeks’ gestation.
Chorionic villi sampling [CVS] for biochemical disorders began in the early
1980s and for the majority of disorders, the diagnosis could be made directly on
CV material, thus alleviating the need for cell culture, and we had an answer
within a matter of days and within the first trimester. In general, the definitive
biochemical diagnosis in an affected child has meant that subsequent
pregnancies in that family can be monitored. However, in some disorders the
relevant enzyme may be tissue specific and easily available fetal material, for
example CV or amniotic cells, may not be appropriate for assay. This is so in the
urea cycle disorders – ornithine carbamyl transferase and carbamyl phosphate
synthase deficiencies, phenylketonuria and glycogen storage disease type 1. The
specific enzyme has to be assayed in liver, and it was in conjunction with
Professor Rodeck in 1982 that Des Patrick in the lab at Great Ormond Street
undertook the first prenatal diagnosis for an ornithine carbamyl transferase
deficiency on a fetal liver biopsy at 19 weeks’ gestation.119 It is in this sort of
disorder that we have now moved on to the DNA analysis and this is obviously
the method of choice for prenatal diagnosis. Once the enzyme deficiency is
proven, and the mutation in the family established, mutation analysis of CV can
be offered.
Of equal importance is the fact that, within a family, mutational or linkage
analysis now allows the definitive determination of female carriers of the X-
linked disorders, thus preventing unnecessary prenatal diagnosis in normal
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females. Most of the biochemical disorders are inherited in an autosomal
recessive or X-linked recessive manner, they are very rare, and generally only after
the birth of an affected infant is a specific genetic risk in a family recognized.
Marcus spoke about mass screening programmes in neonates. We have been
offering these – that’s part of genetic testing as I see it – for phenylketonuria and
congenital hypothyroidism. In the UK they have been offered since 1969 and for
some disorders with a high incidence in certain populations, for example
Tay–Sachs disease in the Ashkenazi Jews, mass screening by enzyme analysis has
proven effective in determining heterozygosity. It took a while for this to take off
in the UK; we tried it in the 1970s and really we had a very low take-up rate, but
now people are becoming more informed and a little bit more, I suppose, liberal
within that religion, we are, in fact, getting more and more to test these days.
Tay–Sachs disease is unusual. In the majority of autosomal recessive disorders it
is not possible to identify carriers by enzyme analysis with certainty. In a family
where the mutations are known, heterozygotes can be accurately identified and
certainly some individuals that were designated as carriers on enzyme analysis
years ago have proved not to be carriers once mutation analysis has become
available, and vice versa. So we have moved on in the last 25 to 30 years and seen
these enormous advances. We now have very sensitive and varied techniques for
assaying metabolites in tissues and fluid. The enzyme defect is being characterized
in more and more disorders, and this, in combination with the huge advances in
DNA technology, mutational and linkage analysis, means that we can now offer
accurate genetic testing in more than 400 disorders. Thank you.
Pembrey: Something I particularly remember about the 1970s and 80s was the
repeated attempts, driven by families wanting to know their carrier status,
individual attempts to use biochemical measures for heterozygote detection, but
would it be fair to say as a sort of general view here that that never came to
anything really very reliable, did it? There was a lot of effort but you didn’t end
up with anything very useful. It never really got into the regular testing side.
Young: No, but we are being asked more and more to test the carrier these days.
If you can only offer it on an enzyme test they still want you to do it.
Edwards: An enormous amount of use was made of creatine kinase in Duchenne
and although there were four laboratories certainly in the UK, including Great
Ormond Street, which could do this accurately, there were a number of others
that couldn’t and most of the people who were told they were carriers were
misinformed, without any doubt. That, I think, is a fact.
Pembrey: Yes, I think that’s an important thing to record.
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Professor David Galton: One of the sad things about Bart’s, apart from
Governments trying to close us all the time, is that there is almost nothing to see
of Archibald Garrod there. There’s a ward called Garrod Ward and Professor
Besser has got photographs of Garrod, and original urine specimens showing
alkaptonuria. Garrod really was a pioneer; he was 20 years ahead of his time.
When Beadle and Tatum made similar discoveries in Neurospora, a bread mould,
they got the Nobel Prize for it; but very graciously at their presentation speech
they gave full acknowledgement to Garrod, saying that all they had done was the
same experiment as Garrod, not in humans, but in a much easier experimental
model, the bread mould. 
Sir Christopher Booth: I had a signed copy of Archibald Garrod’s original 1909
edition of Inborn Errors of Metabolism,120 given to Walter Fletcher who was the
first Secretary of the Medical Research Council. After Joe Goldstein got the
Nobel Prize, I gave it to him for his department. 
Professor Matteo Adinolfi: Carrier detection of the Hunter gene was successful
using the hair root test120a or FISH on chromosome spreads. We were providing
these tests at Guy’s for many years. FISH helped to localize the site of the
deletion.121
Pembrey: Hair roots – you are right, there was a hair root approach, based on X
inactivation, and cell selection, you are quite right. Cardiff offered that. 
Povey: It’s not directly related to testing, but on biochemical genetics, I feel it’s
a bit sad we have entirely left out the idea of normal genetic variations – the
contribution of Harry Harris, Bette Robson and David Hopkinson. Although
this work only occasionally led directly to correct diagnosis – for example the
discovery of adenosine deaminase deficiency (ADA) as a cause of severe
combined immune deficiency122 – in the future the idea of polymorphism will
have tremendous implications for genetic testing.
Pembrey: I agree. It’s sad. There are always opportunities to have an additional
one of these, I think it’s difficult to choose how to focus and fully recognize how
it is, and all that work of the Galton Lab.
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Edwards: A factual comment on Archibald Garrod. His great book has had very
few copies sold, and in Biographical Memoirs of Fellows of the Royal Society, it is
not mentioned.123
Pembrey: As I explained earlier we had hoped to cover pharmacogenetics, not
that it’s used very much in clinical practice yet, but there’s always promises,
promises. The key three people (one of whom had to be here, to have it as a major
topic) were not able to come, so we’ve now gone on to consider prenatal screening
and testing, and then go on naturally to pre-implantation genetic diagnosis, where
Britain has made a very important contribution. That will to some extent take us
to the end of high-risk specific family studies. Then we will move a little bit
broader into immunogenetics and blood groups, as genetic testing that impacts
on a much wider area, not only in the blood transfusion type and so on, but on
transplantation and things like that. So we can move towards more multifactorial
broader stuff at the end if there is time. But there are some meaty things to go
through on the prenatal screening and testing side and I just wondered,
Bernadette, whether you would be prepared to kick it off again. As always,
haemoglobin leads, tends to lead, on these developments where we are talking
about single-gene disorders and then we can bring in the cytogenetics afterwards.
Professor Bernadette Modell: You were complaining that people were not
talking enough about their personal experience. So I would like to talk about
personal experience with two things: screening and first-trimester prenatal
diagnosis, which follows on from the developments in DNA technology, the
linkage that you were talking about. The great thing about the haemoglobin
disorders is that you can detect carriers accurately by using simple, conventional
tests. As you were saying, you had problems using biochemical tests to detect
carriers of most genetic disorders, but you could detect carriers of sickle cell
because of their abnormal haemoglobin, and carriers of thalassaemia because of
their small red blood cells. As the possibilities of prenatal diagnosis were
beginning to open up, I used to think that it was a great pity that here we had
thalassaemia and sickle-cell disorders, both extremely common, and people were
desperate for some kind of prenatal diagnosis. You could detect the carriers, but
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you couldn’t provide prenatal diagnosis, because by definition the fetus had fetal
haemoglobin but the disorders you were interested in were disorders of adult
haemoglobin. Some local public health doctors in this country were very
interested at the time (around 1970), and they had started discussions with the
Cypriot community here about the possibilities for carrier testing, just simply for
information, but those discussions stopped around 1973, I think quite advisedly,
for two reasons. One is that war broke out in Cyprus with the Turkish invasion
[in 1974], which diverted the attention of most Cypriots from anything to do
with genetics. The other was that we went to a ‘Cooley’s anaemia’ meeting
organized by the New York Academy of Sciences, where Y W Kan presented the
results of work based on a long-forgotten study, showing that early human
embryos had some adult haemoglobin.124 He had confirmed this finding and
made it more precise by radioactive labelling of red blood cells obtained from
fetuses. Once you knew haemoglobin A was there, you knew that in principle,
you might be able to do prenatal diagnosis. To do this you would have to obtain
some fetal blood, and no technique for doing this existed at the time. In fact, we
were pushed into it. Charles Rodeck who is here will remember all the traumas
that we went through trying to get fetal blood.125
Talking about the involvement of patients, here is what happened to us at UCH
[University College Hospital, London]. We were doing this research, because
women who were at risk, rather than continue an accidental pregnancy,
practically always requested a termination of pregnancy. This both showed their
need and made fetal material available for study. We were therefore collaborating
with Dr Blanche Alter in David Nathan’s group in Boston to see if we could
measure haemoglobin A in these at-risk fetuses, and so detect carriers and
affected fetuses. We got to experiment number 5, when the mother of one of my
patients, who happened to be a British Pakistani paediatric haematologist, asked
me, ‘How are you doing?’. So I said, ‘Well, come into the lab and have a look’,
and I showed her the results. She said, ‘Fine, good’, and went away. Three
months later she rang me up and said, ‘I am pregnant and what are you going to
do about it? If you won’t try to make a prenatal diagnosis on this baby I will have
to terminate the pregnancy, and I want you to try’. So I said, ‘Ahh, we haven’t
really got a technique for obtaining fetal blood, as you know!’. She said, ‘Well, I
want you to try anyway’. So I rang up our colleagues in the USA and they started
laughing, very rudely and very unkindly because they didn’t appreciate our
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problem, as I thought, until Blanche Alter said, ‘Well, the same thing happened
to us yesterday, too’. So we were pushed into developing new techniques, and
then we had to live for some time with fetal blood sampling, which when the
fetus was affected led to a mid-trimester abortion. When that happens to one in
four of your patients, after a period of time it is very difficult to live with. This
made it crystal clear that for us the priority in the whole field was to develop an
early approach that would allow you to escape from the necessity to use red
blood cells, and use some other tissue that could be obtained earlier on in
pregnancy, to achieve a prenatal diagnosis. Our awareness of the importance of
developing an early approach was heightened by the fact that we were dealing
with thalassaemia, which is common in developing countries, and it was clear
that the techniques we were using would be completely inapplicable where this
disorder was most common. I have just checked with David [Weatherall], and
he agrees with my impression that the first serious clinical application of the new
DNA technology was to allow us to move from second- to first-trimester
prenatal diagnosis. This has been immensely important because once developed,
in principle, these techniques could be made available in practically any country,
to practically anybody. In addition all the other approaches for prenatal
diagnosis, using chromosomes, using biochemistry, using DNA, were able to
piggy-back on this development to move to earlier testing. 
I think it will interest the historians that we were very clear at the time that this
switch from mid-trimester to first-trimester diagnosis could only happen with
haemoglobinopathies, and that gave us a feeling of responsibility. This wasn’t
only because they were the first inherited disorders to become detectable by
DNA methods. It was largely because we had such an absolutely gruesome
prenatal diagnosis method, which was technically difficult and involved a high
risk (about 7 per cent) of fetal loss, as well as leading to mid-trimester abortion.
Everybody else was working with amniocentesis, and the risk of fetal loss
attached to that was of the order of 1 per cent. When you have got a very safe
technique, it’s extremely difficult to move to another technique, which may
theoretically be ever so much better, but with an unknown, probably higher risk.
You have to take the risk of raising the risk for your patients, before it can drop
again. The risk for our patients was so high anyway that we were the only people
involved in prenatal diagnosis who were in a position to tackle this transition.
Since you want reminiscences, the way it all started was because we had been
working with Bob Williamson at St Mary’s Medical School [London], to see if
he was looking in parallel at material from our prenatal diagnoses to see if he
could locate linked polymorphisms. One day he rang up and said, ‘We have got
Genetic Testing
45
Genetic Testing (v19)  3/11/03  8:46 pm  Page 45
it’, so I went over and got a copy of the photo of the gel, took it to our
obstetrician, Humphry Ward, and said, ‘We are on, we should start going ahead
now’. So we started working with women having first-trimester social abortions
in order to obtain placental material in the first trimester. When I talked to our
obstetricians (not Charles), they said, ‘It’s been tried before; it doesn’t work and
there’s too much risk’. I said, ‘But you don’t realize how little material you need’.
Obstetricians think in big terms and they deal with big pregnancies. So I went
away and designed a tool, and put it in our obstetrician’s hand and said, ‘That’s
the kind of thing I want you to look at’. ‘Oh,’ he said, looking at it critically, ‘That
won’t do at all’. He went off and started working with Portex126 to design an
instrument that would do the job. The result was a simple catheter that could
produce a sample of chorionic villus material on which a DNA diagnosis could
be made. John Old (in David’s laboratory) did the first three cases and we were
very lucky this time. The key question was not whether you could diagnose an
affected fetus in time for a first-trimester abortion, but was whether you could
make a diagnosis of unaffected fetus and the pregnancy would continue normally.
The Lancet paper, published on 25 December 1982, described the first
pregnancies in which that happened.127 By April 1983 the Pope had made a public
announcement that it doesn’t matter at what stage of pregnancy you do a prenatal
diagnosis, it’s still not acceptable.128 Of course that wasn’t the end of the story. We
were still stuck with a DNA-linkage method, which, as David was reminding me,
was a very difficult technique to work with. It was when PCR came along that
people really started coming from places like Pakistan to learn how to do it. 
I have talked about fetal sampling, rather than screening, because there’s no point
in screening people unless you have got something to offer, and this illustrates the
succession of steps in moving from the hopeless to the undesirable to acceptable
techniques. I certainly felt like Hercules [Atlas] who got stuck with holding up the
sky, and when he finally managed to dump it on somebody else, it was the most
enormous relief. That was the way our whole team felt when we knew that we
could move from second to first-trimester diagnosis. Second-trimester diagnosis
was a terrible method for everybody involved, not only for the patients.
Pembrey: The story of patient pressure, we are going to hear that again as we talk
about pre-implantation genetic diagnosis [PGD]. But Charles, perhaps from the
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fetal sampling side of things, going back to all the things you could do with genetic
diagnosis, you could do haemophilia and others with fetal blood, again was there
a lot of patient pressure? How did it work? Would you have the same pressure?
Rodeck: Undoubtedly, that has been the story of prenatal diagnosis all along
really. People faced with high risk of fetal disease or abnormality wanting to have
a test, hoping that they will get a diagnosis that the baby is normal, or lack of a
diagnosis if you like, but have made up their minds that if it’s affected, they will
terminate. So there has always been a great deal of pressure and we found that
having developed a fetoscopic technique for successful fetal blood sampling and
other substances too, fetal liver as was mentioned, and fetal skin, we were on a sort
of conveyor belt. There were six or eight of these cases a week, many of them from
Cyprus and Italy, and the results in general were very good. I wouldn’t put our
fetal loss rate quite as high as the one Bernadette mentioned, but you know it was
a satisfactory technique that was working at the time and, of course, that meant
you looked very hard before you moved away from it. But the problem was always
the second-trimester termination, which means, people may not all realize that in
this room, that the mothers who are facing this already had felt fetal movements.
So I think one of the very crucial things about first-trimester diagnosis, even if you
get the result in the early second trimester, is that the woman has not felt fetal
movements and that her friends and neighbours didn’t know about it and so
forth. So in general we moved very rapidly to first-trimester diagnosis as well. 
Pembrey: What was the timing? In 1982 (the paper that Bernadette refers to)
where were we in terms of chromosome analysis of CVS at that time?
Rodeck: The thing that I think stimulated the West was the paper on CVS from
China in the 1960s from the Anshan Steelworks, where there were no named
authors in true Maoist tradition, but the whole hospital, probably including all the
porters, were co-authors.129 They produced this paper, which, of course, was used for
sex selection. In the meantime there were several groups of us in London already
looking at CVS, but there was another paper from the Eastern Bloc by a Hungarian
who had been working in Moscow called Kazy and he submitted a paper to Prenatal
Diagnosis in 1981, which Malcolm had to rewrite and which contained a few
diagnostic cases.130 I met Zoltan Kazy in a taxi once and he was extremely grumpy
because he always felt that people in the West didn’t recognize his achievement and,
of course, he disappeared, probably to the Gulag unfortunately.
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Malcolm Ferguson-Smith: I had a letter from him last week.
Rodeck: Oh excellent, was it postmarked Gulag? 
Ferguson-Smith: He is back from the Gulag. He still feels disgruntled and has a
review article. Now if you could help me with his address, because my secretary, who
is very good at opening my letters, threw away the envelope with the address on it.
Rodeck: I am afraid I can’t. 
Ferguson-Smith: His paper was published in 1982 in Prenatal Diagnosis.131 Bob
reviewed that paper, I think, and his own paper came out in the Lancet shortly
thereafter, that paper about CVS and haemoglobinopathies.
Modell: You sent me that paper to review too, and it was very interesting,
because you said it was from behind the Iron Curtain in those days, and nobody
knew what to make of it. The interesting thing was that when I was reading it I
felt, oh gosh these people have got just the same problems as we have, so I thought
it was a very good and realistic paper and told you so, and you published it. The
question the discussion is raising now is why did this development happen when
and where it did? Why did it happen for haemoglobinopathies? Why did it happen
in Russia? And why did it happen in China? It happened in China because in
China they hadn’t got any facilities whatsoever. They did it without ultrasound,
they did it blind, just by touch. I’ve talked to the people who did it at WHO
[World Health Organization]. [From the floor: But all they were going to do with
the villi was to sex the fetus]. Yes, they did it blind and they used the Barr body for
sexing the fetus. They stopped when they found out that almost all the female
pregnancies got terminated. Subsequently, it turns out that doing it blind, you can
get a lot of fetal abnormalities. But they developed this approach because they
hadn’t got the kind of technology that we had. Exactly the same thing applied in
Russia. Amniocentesis was an extremely unsatisfactory method for them, because
they had to buy culture media from the West and very often it didn’t work. They
found out later that when a firm had a batch of medium that had nearly expired,
that was the batch that went to the East. So they couldn’t use tissue culture reliably
for prenatal diagnosis and were forced to look for alternatives. So it’s when you are
really up against it that you can afford, or even are forced, to move away from the
accepted conventional and safe techniques with problems, to new areas. 
Weatherall: Bernadette’s account of the development of prenatal diagnosis of the
haemoglobin disorders makes it sound as though it was all calm and easygoing.
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In fact, it was anything but! We felt that David Nathan in the USA and
Bernadette Modell in London were badgering us to take our globin-synthesis
technique beyond its limits and that to demonstrate, reliably, 2 per cent of 
β-globin chain in a fetus at 15–20 weeks was really pushing its limits. I know that
Y W Kan, who was one of the earliest to try, had many sleepless nights waiting for
the outcome of pregnancies in which he had used this approach and I remember
the hours we spent clearing up the globin-synthesis plots of some of the first cases
that were analysed by us following prenatal diagnosis in London. I think we would
have preferred more work to be done to improve the technique before applying it
to patients, but Bernadette’s extraordinary drive and enthusiasm would simply not
let this happen; without her push, which was motivated entirely on behalf of the
patients and parents, we would probably have gone on improving the technology
for a further ten years; in the event, it worked remarkably well. I seem to remember
we went through the same qualms when the chorionic villi era appeared. 
Modell: If you want to persuade the scientists, the great thing is the hands-on
approach. I remember coming up to Oxford to see John Old with a little pot
containing a set of chorionic villi and holding it up to the light and shaking it
and saying, ‘Look, John, that’s what we are talking about’, and I saw his eyes go,
‘Ooh! I think I could handle that’. 
Adinolfi: I would like to mention, very briefly, a new approach about performing
prenatal diagnosis by non- or minimally invasive techniques. The test is based on
a method introduced in 1971 by L B Shettles, an American obstetrician, who
claimed that he could detect fetal cells (trophoblastic cellular elements) retrieved
from the endocervical canal at early stages of gestation.132 He suggested that
trophoblastic cells are first shed into the uterine cavity and then in the
endocervical canal where they could readily be found. Several years later Charles
Rodeck and I decided to see whether this phenomenon was frequent.133 We
collected transcervical mucus from pregnant women between five and 13 weeks
of gestation, and found fetal cells in 60 to 80 per cent of samples according to
the method used for their collection. In a recent paper in Prenatal Diagnosis,
Amiel and collaborators claim they could detect fetal cells in 98 per cent of
samples collected with a cytobrush.134 So, this seems a promising noninvasive
prenatal technique that can be used for analysis of fetal chromosome disorders
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by FISH or single-gene diseases by fluorescent PCR. Unfortunately, a few years
ago we discovered that this approach had been misused in South Korea for fetal
sexing (with 95 per cent success) and for aborting female fetuses.
I would like to mention another approach for rapid prenatal diagnosis of
numerical chromosome disorders, based on PCR, which has not been mentioned
by Paul Polani. The technique, called quantitative fluorescent PCR (QF-PCR) is
based on the amplification of highly polymorphic DNA sequences (short tandem
repeats, STRs) specific for chromosomes 21, 18, 13, X and Y. STRs are amplified
and a fluorochrome is incorporated into the PCR products, which are then tested
by a DNA scanner. In only a few hours it is possible to perform prenatal diagnosis
of numerical disorders.135 QF-PCR is now used in many genetic centres in the
UK, Italy, Spain, Portugal, Germany and Austria as a preliminary test before
conventional cytogenetic analysis, in order to reduce the anxiety of the parents.
But, when applied to test samples from pregnancies at high risk, the QF-PCR
results can be accepted as definitive evidence of fetal chromosomal abnormalities
and, eventually, termination of pregnancies may be performed if required. 
Pembrey: Just remind me, what cells are you doing these tests on?
Adinolfi: You can use any type of fetal cells.
Pembrey: But which ones are they using in this screening test?
Adinolfi: Amniotic or chorionic cells, for example. And, as I have mentioned,
trophoblastic cellular elements present in the endocervical canal of pregnant women. 
Pembrey: But not maternal blood?
Adinolfi: Barbara Pertl and Diana Bianchi have used QF-PCR for the detection
of fetal cells in maternal blood samples. I am sceptical about the claimed success
of using this type of approach for prenatal diagnosis, since too few fetal cells are
present in the maternal samples, and their isolation will be quite time consuming
and expensive. It has also been claimed that fetal erythroblasts can persist for
many years in maternal circulation. Were this true, fetal cells from a previous
pregnancy would hamper the accuracy of the tests and produce false results!136
Pembrey: It’s very interesting; these fetal cells in maternal blood, the sort of way
things have gone. Because I remember doing a lecture tour in South Africa in 1981
and saying that it’s a toss up as to whether it’s going to be analysis of chorionic villi
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samples that’s going to really take off, or whether that’s going to be superseded by
extracting fetal cells from peripheral blood. So at that time there was a feeling that
they were sort of level pegging. I don’t know if others had that feeling.
Rodeck: We had that feeling for quite a long time. When I was a medical student
there was a man at Northwick Park called Barnes, an immunologist who was
looking for fetal cells in maternal blood. 
Ferguson-Smith: Two comments. First of all can I ask Matteo to tell us what the
effect of this screening for sexing was in Taiwan?137 I understand that the number
of pregnancies screened for gender selection was over 20 000 per annum. 
Adinolfi: Fetal sexing with any method has now been forbidden by law in Taiwan.
Ferguson-Smith: But the effect on the population sex ratio at birth was
extraordinary, what was it, 1:1.6?
Adinolfi: I don’t know. It has been difficult to get clear data on the use and results
of the noninvasive approach that was carried out in the private clinics. 
Ferguson-Smith: Then, following up about fetal cells in the maternal
circulation, results have been very disappointing over the last few years. I don’t
think there is going to be a prenatal test using nucleated red blood cells
containing embryonic haemoglobin, because people have found to their cost
that adult maternal cells, progenitor cells, can also produce fetal and embryonic
haemoglobin. What is more promising recently are two approaches, one is the
actual DNA in the serum itself, and if you can identify suitable markers you will
be able to make a genetic diagnosis. The other point is going back again to
trophoblast. Trophoblast seems to be much more in vogue because there are
good antibodies to identify the occasional trophoblast cells in the maternal
blood and that looks a much more promising mechanism. I would put my
money on DNA in the circulation, derived from breakdown of placental cells,
and apoptosis in fetal and placental cells.
Adinolfi: Malcolm, do you believe that fetal DNA in maternal plasma is mainly
derived from trophoblastic cells that are shed during pregnancy in the maternal
blood reaching the lungs and forming emboli where they are rapidly lysed? 
Pembrey: I think the interesting thing in drawing that part of the discussion to
a close is again in this case in Taiwan or China, it’s the patient pressure in a sense,
that is driving some of the people to develop these techniques.
Genetic Testing
51
137 His and Adinolfi (1997).
Genetic Testing (v19)  3/11/03  8:46 pm  Page 51
Rodeck: Matteo has brought us up to the sunny uplands of the 21st century
really, and I think you wanted to know a bit about the dark ages of the 20th
century. You asked about the application of cytogenetic diagnosis using
chorionic villi and this was extremely difficult. In the early 1980s as far as I am
aware in London there were three groups, UCH, I was at King’s, and there was
St Mary’s with Dulcie Coleman in cytogenetics and Bob Williamson in
molecular genetics. Dulcie had been working on a method of culturing chorionic
villi, which is, in fact, very difficult. The trophoblast covering the villi is very
difficult to culture and it turned out that you could only get success if you
digested off the covering trophoblast and cultured the mesenchymal core, or
perhaps the endothelial cells of the capillaries in the core of the villus. While
attempts were going on along these lines, the whole situation was transformed
by Simoni in Milan138 who developed a method for obtaining chromosomes,
chromosome analysis, on metaphases from spontaneously dividing cells in the
cytotrophoblast. So he also digested off the trophoblast, but then developed what
is called a direct preparation, which in theory you could do in two or three hours.
In practice most people would culture over night, and then perform this analysis.
That meant it transformed cytogenetic diagnosis, because you not only did the
test several weeks earlier than amniocentesis, you got a result in a day or two,
rather than in three or four weeks, which a karyotype took in those days. So then
that was quite widely adopted, but it became apparent that this tissue, the
cytotrophoblast, had a high level of mosaicism, or at least high compared with
amniotic fluid. So to cut a long story short, nowadays the chorionic villi are not
regarded as the best tissue for a cytogenetic diagnosis on the fetus, and we have
gone back to amniocentesis, particularly because we now have PCR
methodology to do specific chromosomal diagnosis. 
The other aspect that CVS revolutionized was biochemical disorders, because as
Liz [Young] knows, many of the techniques that people like her have developed
for amniotic fluid, could quite rapidly be modified for chorionic villi. So even
before all the genes were cloned for these conditions, very rapid biochemical
diagnosis could be done in the first trimester, on chorionic villi. 
Adinolfi: Do you think the Chinese were doing chorionic biopsy or were
collecting cells from the endouterine cavity, because they were not using
ultrasound? It’s possible they were just getting into the endocervical canal and
collecting fetal cells there. 
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Pembrey: We are going to move forward now into the pre-implantation stage,
because this is an important area where Britain has made pioneering
contributions. I am going to take Chairman’s privilege to tell a story about a
meeting, a workshop, that was held by Ciba, the Ciba workshops – invited
workshops that have played a very important role in a number of these
developments. I know the date, it was on the 7 November in 1986, it was
certainly a Thursday, because I carried the Thursday’s Nature with me. Earlier
that year, in the summer, there had been a genetics meeting in Berlin and
everybody was desperate to hear about the PCR. I think it was Henry Erlich
from California (I think he was in Genentec then or something) but he was in a
little side room. There was the plenary session in Berlin with hardly anybody
there. Everybody was trying to get into this small theatre, with people relaying the
information that was being said, out into the corridor to the crowd, about this
amazing PCR technique. So that was in the summer, and then we had this Ciba
meeting, and Bernadette was asked to speak. Bob Edwards was involved on the
IVF [in vitro fertilization] side, and Anne McLaren, who was, I think, one of the
people who brought the obstetricians, and I think Charles was there. Bernadette
was asked to state whether or not there was a clinical need for this pre-
implantation diagnosis, and she quite simply, in her characteristic way, asked the
patients what they would most dearly like us to develop, and they said, we would
like to be able to start the pregnancy knowing that we have got a healthy baby, or
a baby without the genetic problem. So that was the pressure from the patients. 
I was asked to talk about the genetics in general terms, but I had with me a paper
in Nature by Henry Erlich, saying that they could do PCR and get typing of HLA
genotypes on as few as 75 cells,139 and when I said this, Bob Edwards jumped up
and danced around the room, saying 75 cells, 75 cells, we are going to be able to
do it! Because he had earlier said I don’t think it is on, we can’t give you geneticists
enough cells. So that was a key moment for me, and that was in November 1986. 
At that time we were just beginning the big debate that led up to the Human
Fertilisation and Embryology Bill and Act in 1990.140 So it was a four-year period
and this was a key time in which the technology and the ideas came together. But
for that bill to be carried through, everybody is agreed, I think, that prenatal,
pre-implantation genetic diagnosis was the main thing that was being
championed, indicating the positive side of being able to do embryo research on
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pre-implantation embryos. I know Alan Handyside was very involved in those
early studies at Hammersmith and perhaps you could take it from there?
Professor Alan Handyside: The attempts to develop pre-implantation genetic
diagnosis [PGD] involves the use of assisted reproduction and is an interesting
story, because for the first time it brought human genetics and assisted
reproduction together, raising challenging technical and ethical issues.
Nevertheless, as you have just pointed out, it occurred in the mid- to late-1980s;
against a background of an intense debate on whether or not we should legislate
within the UK in favour of human embryo research.141 I believe it played a key
role, as I will explain, in helping to persuade people that perhaps there were
benefits to be gained from allowing human embryo research. In fact, when the
legislation went through, one of the specific reasons for which human embryo
research can be allowed is for understanding the aetiology and diagnosis of
genetic defects at early stages of development. On a personal level, my
involvement goes back to slightly before the Ciba meeting, to 1985. I have
always credited Anne McLaren for talking about this at a meeting.142 I think she
must have had privileged access to the rumours that had been going round about
the success of the polymerase chain reaction, and in the audience was a young
clinician, Richard Penketh, who at that time had a fellowship and was working
with Dorothy Gibbs, and the senior professor at the CRC [Clinical Research
Centre], Richard Watts, on inherited metabolic disorders. He had one patient
that he was particularly interested in helping and used to show pictures of the
affected teenage boy bound to a wheelchair for his own protection. The parents
had tried to use prenatal diagnosis to avoid having another affected boy and had
something like, I think, six terminations of pregnancy without success. So this was
the major stimulus for the use of assisted reproduction – the hope of bringing the
diagnosis back to a stage at which we could then go on and select embryos that
were unaffected, transfer them back to the woman’s uterus and, as Marcus said,
really fulfil this dream that couples could start a pregnancy knowing that it should
be normal. 
This was a very interesting coincidence, because at the time I was working at the
MRC Experimental Embryology and Teratology Unit. I wasn’t working in this
area at all, but had just, working with Martin Hooper in Edinburgh, developed
the first gene knockout mouse using embryo stem cells, mouse embryonic stem
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cells.143 This was achieved independently by Martin Evans at Cambridge,144 with
whom I had worked previously. The gene that we had chosen to knock out was
hypoxanthine–guanine phosphoribosyl transferase (HPRT) and the goal was to
create a model of Lesch–Nyhan syndrome, which was precisely the condition
that this patient of Richard’s was at risk of transmitting. Towards the end of that
work when we were racing really to prove that we had the knockout mouse, we
approached Marilyn Monk because she had a very sensitive biochemical assay to
prove that the gene, in fact, had been knocked out, and the mice had no HPRT
activity. We did this by isolating individual intestinal crypts and individual
hairs.145 We spoke a little earlier on in terms of biochemical genetics, hair follicles
were still being used to determine carrier status in Lesch–Nyhan syndrome at
that time, and hence I had various discussions with Dorothy Gibbs as to whether
her tests would be sensitive enough to get down to the single cell level. But
clearly Marilyn Monk had, over a period of many years, refined this technique
to analyse, mainly using this X-linked enzyme, the timing of X inactivation in
early development. So although the HPRT knockout mouse turned out to be a
failure in terms of replicating the symptoms of Lesch–Nyhan syndrome, or for
providing a vehicle for testing therapeutic strategies, it was clear that we should be
able to use this mouse model to develop techniques that would be necessary for
pre-implantation genetic diagnosis, such as to biopsy cells from the early embryo
and single-cell analysis. Ironically, although this occurred against a background in
which PCR had just been discovered if you like – and that’s controversial in itself
as to whether Kary Mullis was, in fact, the discoverer – we used a biochemical
approach initially, and so did the group in the USA, who were the only group I
think in the USA that were interested at that time, and that was a collaboration
between Eugene Pergament, who had been very much involved with CVS, and
Yury Verlinsky, who is still one of the major players in the USA. 
At this point, I would just like to give credit to the first attempt, or the first
recognition that pre-implantation genetic diagnosis might be possible, to the
pioneer of IVF itself, Bob Edwards. I would be interested if anybody else knows of
any other precedents. In 1968, really within the context of animal embryo genetics
and the commercial needs to either pre-select the sex of bovine or sheep embryos,
for obvious commercial reasons, attempts had been made for many years to
differentiate between X and Y bearing sperm. Bob Edwards got together with his
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first PhD student, Richard Gardner, to attempt this in the rabbit. This was a very
fortuitous choice, because the rabbit pre-implantation embryo can get to several
millimetres in size in vitro. The results were published in Nature in 1968,146 in
which they performed embryo biopsy, by snipping a piece of trophectoderm with
a pair of iridectomy scissors from the blastocyst and then used the presence of the
Barr body to identify female embryos. After they transferred them back to
recipients, they demonstrated that they had correctly sexed all of the embryos. 
I went up to Cambridge in 1971 and it was through the lectures that Bob
Edwards gave that I decided on a career in embryology. This was only three or
four years following publication of this work. Looking back after many years at
that paper they do explicitly say we are aware that it may be possible to use it in
X-linked conditions and, in fact, speculate about combining chromosomal
analysis with enzyme analysis to look at human disease. Interestingly, one of the
offspring was anencephalic, raising worries about the biopsy process. Why
biopsy of the trophectoderm would cause any problems isn’t clear, but I believe
the feeling, Bob Edwards’s feeling, was that there was a high level of anencephaly
in this particularly strain of rabbit. So the original attempt certainly arose out of
attempts to sex embryos in farm animal species and go back as far as 1968, but
modern attempts really were stimulated by PCR. 
So as Marcus has pointed out, as a result of Richard Penketh’s interest, Anne
McLaren and Richard Penketh wrote a very stimulating review about
possibilities.147 He then approached David Whittingham who was the director of
the unit that I was at, and so because I had the model of HPRT, and was already
collaborating with Marilyn Monk, we then went on to show that we could
indeed sample cells at cleavage stages. We had to culture them to the appropriate
stage, because Marilyn knew in detail when you would be able to ascertain the
embryonic genotype from the enzyme activity. One of the problems about
biochemical analysis in this period is that most of the enzyme activity is inherited
in the oocyte cytoplasm and persists for a variable period of time. So you had to
be sure that the maternally derived enzyme had degraded and that any enzyme
activity that you picked up was, in fact, from zygotic gene expression. But she
had already done many experiments in which the timing had been established,
and in fact we were able not only to pick out HPRT-deficient embryos and prove
this by transferring them, but also Marilyn and I went on to show that because
you can see a two-fold difference, measuring this X-linked enzyme, you could sex
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on this basis too. So this was entirely non-PCR based. Then we all got together
at the Ciba Foundation meeting, and of course shared in the excitement of the
publication finally describing PCR and demonstrating the possibility of
analysing as few as 75 cells. At that stage we had no idea how many cells there
were in the human blastocyst. It wasn’t until 1989 that I did some studies that
showed that indeed by the time you get to the end of the first week of
development, you have hundreds of cells in the human blastocyst on different
days, and indeed you might well be able to use PCR to analyse genetic defects. 
So having got involved in the field, I then had to make a decision about how I
took the work forward. Clearly, the knockout mouse had not proved to be a
model for the human disease. Martin Hooper went on to knock out genes
involved in cancer, the retinoblastoma gene and so on, and I decided to follow
up on the pre-implantation genetic diagnosis and realized that what it required
was to move to an obstetric department and really get involved with assisted
reproduction clinics. So I approached Robert Winston, now Lord Winston, at
Hammersmith Hospital about this. He was very excited about two projects,
one was human embryonic stem cells, and I had been very involved during the
years in the mouse, but also in PGD [pre-implantation genetic diagnosis], and
it ended up that we put most of our efforts into PGD, because we didn’t have
the ability to culture human embryos for very long at that time. So it was, in
fact, almost coincident with the Ciba meeting that I moved across to work
with Robert. 
We had two clear objectives to begin with. The first was to develop methods for
embryo biopsy. Anne McLaren was the key figure here. She was running the
Interim Licensing Authority [for human in vitro fertilization and embryology],
and the challenge she gave us was to develop an embryo biopsy strategy that
would not threaten the development of the embryos. So I set about doing this,
against, as I say, a background of very intense media interest in human embryo
research. Robert was very keen to interact with the media and really worked very
hard to try to persuade people. Looking back on that time, it was really a
nightmarish period of my life, because we literally had several film crews through
every week. So we were literally being filmed during the experimental phase; as
we were developing the biopsy techniques, they were being filmed, and we were
being interviewed about the possibilities. But in the end this paid dividends and
I kept cuttings from this period of time and collected them altogether. I had a
friend who worked in the Home Office – obviously the Home Office took a lead
on this legislation – who passed me their own cuttings, and after the debate in
the House [of Commons], all these papers were passed to a sociologist in York
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[Professor Mulkay] who studied the language used, and how the debate evolved
over this period of time. So it had an academic spin-off. 
The second thing that I decided very early on, is that you couldn’t do this at the
blastocyst stage. We weren’t able to get pregnancies by transferring embryos at
that stage, so we had to go for single cells biopsied form early cleavage stage
embryos. We therefore had to develop PCR. So working with Ted
Tuddenham’s148 group – the names keep recurring here – who was then at the
CRC and had moved down to Hammersmith, we were finally able to use a Y-
linked repetitive sequence to identify males and used this in five couples at risk
of X-linked disease, having published work that showed that we could biopsy the
single cells safely. The first couples were treated in September of 1989. We had
no idea whether they would get pregnant at that stage. They were fertile couples,
so we were optimistic from that point of view. However, we were making a large
hole in the zona149 and had no idea whether the embryo would be lost. We knew
from animal experiments that this could destroy the embryo. In fact, in the very
first case a single embryo was transferred and the couple had a biochemical
pregnancy, and the pregnancy rate in the other couples was exceptionally higher.
We then had a very nervous period of waiting to have the diagnosis confirmed.
We counselled all of the couples that this was very early and experimental. So
they went on to have the diagnosis confirmed by CVS in the majority of cases.
When we had the results from several couples confirming the sex as female, I
approached Nature to see if they would be interested in this publication.
Miranda Robertson, who was at the time Assistant Editor, went off to talk to
John Maddox [Editor] and really because of the background of the intense
debate on human embryo research, they said that they would be very interested
but wanted to make sure it was published ahead of the debate in the House of
Commons. So we were literally working day and night to write the paper against
these tight deadlines. The peer reviewers had already been set up, and it was
probably one of the first papers to be peer reviewed by fax. It was submitted and
accepted, after peer review and corrections, in only two days, because John
Maddox was absolutely clear that the public should be aware of the potential
benefits of embryo research.150 In the week of publication he organized a press
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conference and the two women who carried the first pregnancies came along
because they wanted to support the work and enable other couples to benefit
following PGD. I think they were very brave and both of them were heavily
pregnant with twins, but it had a significant impact on the press conference and
their story was featured on the front page of the Daily Telegraph the following
day. The following week at the end of the debate, even Margaret Thatcher went
through the aye lobby and voted to allow human embryo research, which was
carried by a substantial margin. 
Pembrey: Cathy, if you would like to talk a little, if you have got any comments
about your early work with Marilyn that led into this, and then we will move on
to the chromosomal side.
Mrs Cathy Holding: I seem to have been involved in all these various aspects of
genetic testing, going right back from testing for HPRT activity in hair roots and
cell lines from skin biopsies to the development of an HPRT assay for use in
prenatal diagnosis of Lesch–Nyhan syndrome by chorionic villus biopsy.151 I then
moved on to Marilyn’s lab, where she had developed a single-cell double
microassay for the X-linked HPRT and autosomal APRT for her X-chromosome
inactivation studies throughout the 1970s. Marilyn had already developed
various single-cell procedures for studying gene expression in pre-implantation
embryos long before people began to talk about pre-implantation diagnosis. At
the time I joined her lab, we were developing single-cell assays for adenosine
deaminase – the enzyme that is deficient in some forms of severe combined
immunodeficiency disease (SCID).
When the discussions of the feasibility of pre-implantation diagnosis began,
Marilyn knew she was already doing this in her diagnoses of HPRT levels in
single embryos, and she only needed to gear her experiments across to this more
clinical arena. I can remember Alan coming into Marilyn’s lab in the mid-1980s
to help with the blastomere biopsies, and both of them at the lab bench. Alan
biopsied the single blastomeres from the embryos, and Marilyn then carried out
the single-cell molecular assays. Initially they used a mouse model for
Lesch–Nyhan disease and diagnosed the HPRT-deficient embryos, and later they
also used Marilyn’s dosage analysis of X-linked HPRT also for the sexing of pre-
implantation embryos. After that, PCR hit the headlines as a really powerful
technique for amplifying small-defined regions of DNA. Marilyn decided that it
would be a good idea to try to use PCR to amplify single-copy genes in single
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cells, also for use in pre-implantation diagnosis. Alan points out that they did
PCR on multiple-copy sequences on the Y chromosome for the purpose of
sexing in pre-implantation diagnosis, but Marilyn could see great potential for
pre-implantation diagnosis in amplifying single-copy sequences in single cells for
direct analysis of genetic defects, as sexing is only relevant for sex-linked diseases.
So we developed our single-cell nested-PCR technique for detection of defined
sequences of DNA and showed that we could diagnose β thalassaemia by assay
of a sequence of the β-globin gene in single blastomeres from the pre-
implantation embryos. We were the first to show that PCR could be used on
single-copy genes in single cells using nested PCR.152 Cui and colleagues also
reported successful single-cell PCR using two-primer PCR on single sperm at the
same time, but they needed to use a radioactive hybridization technique to see
the products. We were directly able to see the products of nested PCR in an
agarose gel, greatly speeding up the process for a clinical setting. 
Since the research on embryos was an ethically sensitive issue (human embryo
research was at that time being debated in the House of Commons), Marilyn
could see the potential for using PCR for pre-fertilization diagnosis (that is,
diagnosing a genetic disorder in the oocyte before fertilization by removing and
analysing its first polar body, leaving the oocyte intact for in vitro fertilization
after diagnosis is completed). We showed that it was possible to carry out the
analysis of a single-copy gene, this time using a PCR strategy that detected the
sickle-cell mutation in β globin, in the first polar body of a human oocyte.153 We
could deduce from the genetic status of the first polar body the genetic status of
the oocyte, and thus diagnose whether the oocyte carried a sickle-cell mutation.
This was an important breakthrough for the debate, because we had shown that
we could do the diagnosis without having to do any research on the embryo, and
we were using a human oocyte now rather than mouse-model systems. In fact,
the single-cell assay we developed to detect the human sickle-cell mutation in the
polar body of the human oocyte (and in any single cell) is widely used in pre-
implantation diagnosis labs today. 
Marilyn has played a major role in the development of techniques for the pre-
implantation diagnosis of genetic disorders, initially in mouse models and, by
1990, in the polar body of the human oocyte.
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We were successful in the first instance, where so many other labs were not able
to do single-cell PCR due to contamination, because we went to extreme lengths
to avoid cross contamination with PCR products.154 Both myself and Marilyn (in
separate laboratories) then went on to do relevant quality-control experiments to
evaluate carefully the accuracy and efficiency of the diagnoses – so important
before offering these procedures in the clinic. 
Pembrey: I certainly remember Marilyn saying, and perhaps you would like to
corroborate this, but one of the things that drove her wasn’t so much the patients
driving her to develop these micromethods, it was her respect for animals, and
not wanting to sacrifice an unnecessarily large number of animals, to take a little
clip off the tail of a mouse, rather than kill it.
Holding: That’s absolutely right, yes. Long before the development of the
molecular procedure for pre-implantation diagnosis, Marilyn had been setting up
molecular analysis of gene expression in pre-implantation development. Before
she attempted this, however, she decided to work on the molecular microassays,
to make these assays sensitive to the single cell, so that a great deal of information
could be gained from the embryos of a single pregnant female mouse – to use  one
single mouse instead of hundreds, as had been used previously. 
Pembrey: Joy, chromosomes were a rather different sort of story I seem to remember?
Professor Joy Delhanty: In the beginning it wasn’t chromosomes. In the
beginning my involvement began in parallel with Alan’s work on developing the
PCR method for sexing embryos. Then Richard Penketh and I were working
trying to develop a non-radioactive method of in situ hybridization to detect the
Y chromosome in an interphase nucleus. That was working quite well, but the
problem was it was all taking too long, as we thought then, taking about 48
hours to detect the Y chromosome and there was quite a lot of background. So
we thought, well, the PCR had won the race and that was going to take over. But
then along came FISH, fluorescent in situ hybridization. I took on a young
student called Darren Griffin, in the lab in the late 1980s, without really
knowing whether FISH was going to work at all – there were just a few abstracts
from meetings and things. He got that going in our lab and we were able to
develop FISH to detect not only the Y chromosome, but also the X chromosome
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simultaneously (see Figure 2),155 and that proved in the slightly longer run to be
a more reliable method for determining the sex of the embryo, but also it gave
us an indication of the copy number of the chromosomes present.156 So not only
could you say whether there were X and Y chromosomes present in this nucleus,
but also how many there were. So it meant that you could distinguish between
a normal female for instance, and one that would develop Turner’s syndrome,
and only have a single X, and similarly distinguish a Klinefelter XXY from a
normal male. So that was an important advance. From that, we went on to
develop ways of detecting other chromosome abnormalities, mainly for couples
where one of them was carrying a translocation, and this was causing a lot of
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Figure 2: The use of FISH with DNA probes from the X and Y chromosomes to sex human
embryos, by interphase cell analysis. a. Nucleus from a male embryo following dual FISH with biotin-
labelled X chromosome probe (top signal) and digoxigenin-labelled Y probe (bottom signal).
b. Nucleus from a female embryo that consistently had three X signals per nucleus after dual FISH
with X and Y probes. Delhanty (1994): 1224. Photographs provided by Professor Joy Delhanty, 2003.
a. b.
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problems. Often these people were unable to carry a pregnancy, because they
were having many miscarriages, and that sort of led to an application for FISH
– to be able to select healthy embryos for these couples. 
One thing I would like to say is that as far as patient pressure is concerned, it’s
interesting that now we are able to do PGD for the dominant disorders, in
particular the cancer-predisposing genes, that couples who come and ask us if we
can help them. What they say is I want to get rid of this gene from my family, it is
a curse. The people who are worried about PGD in terms of eugenics wouldn’t like
to hear that, but that’s what the families say. Also for things like fragile X, they say
that as well, we want to get rid of it, it’s just a curse. That’s an interesting reflection. 
Pembrey: It’s the phraseology, but in practice I guess you could turn round and
say in a sense they also want to have a healthy child. 
Adinolfi: A very brief note about the use of embryonic cells for the correction of
selected inherited diseases. A few years ago I was talking with Bob Edwards about
embryonic cells, and we came to the conclusion that there was too much
emphasis on and hopes about these cells being used for therapeutic correction of
genetic disorders. Embryonic cells, once differentiated, are expected to produce
histocompatibility antigens, and consequently their use would be limited only to
immunocompatible donors. 
It has been claimed that stem cells from normal adults (such as bone marrow and
brain cells) may differentiate into other types of cell. We do not know why stem
cells from an adult may de-differentiate and differentiate into other types of cell
producing insulin, or other proteins. This topic is still controversial, but if early
results are confirmed, Bob and I thought that the direction to go would be to
induce differentiation in vitro of adult stem cells into specific differentiated cells,
which could then be transplanted into a compatible patient. 
Pembrey: I understand, but I am sure we will have a witness seminar on stem-
cell research, and that there will be just as much time pressure on it. Right away
from the individual families at high risk and culminating with the very early pre-
implantation, stand back a bit now and not forget that genetic testing has also
played its role in medicine more broadly; in immunogenetics and in blood
groups. And perhaps Rodney if you could say a little bit on the HLA side, and
then perhaps Derek Roberts could come in and cover other areas. 
Harris: Peter Medawar once said, ‘We are being progressively relieved of the burdens
of single instances, the tyranny of the particular. We need no longer record the fall of
every apple’. This comment became very apposite to the HLA [human leukocyte
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antigen] field and human histocompatibility because for some time they were
enormously complicated by descriptions of a multitude of serological and cellular
reagents defining putative new and overlapping antigens. In the HLA community a
uniquely enlightened collaboration, in the form of a series of international
workshops, defined the system and incidentally provided the model for future
scientific advances, including those leading to the sequencing of the human genome.
Foremost among the people who initiated and made these histocompatibility
workshops succeed were Walter Bodmer and Julia Bodmer, at first in California with
Rose Paine, but subsequently in the UK with Richard Batchelor and Sylvia Lawler,
and many colleagues in other countries, including Jean Dausset, Roy Walford, Paul
Terasaki and Jon van Rood among others. By sharing reagents and data, ‘apples’ were
found to fall in recognizable patterns that vastly clarified immunology, organ
transplantation and understanding of disease susceptibility.157
With the help of many collaborators, including Charles Rodeck and Bernadette
Modell, who are here, the confidential enquiries showed that the primary care
providers, GPs, obstetricians, internists, etc., often had little knowledge of
genetics, and that many non-genetic clinicians were so concerned with the
management of disease in individual patients that the implication for relatives
and future generations were often overlooked. Non-geneticist healthcare
providers often did not correctly interpret the results of genetic tests ordered by
them, and were poorly prepared to discuss the results of testing. Many were
woefully unaware of ethical, legal and psychosocial implications such tests may
have, and were often not in compliance with ethical and clinical guidelines,
especially regarding informed consent for testing. 
Fortunately Cedric Carter, with others in the Clinical Genetics Society, had
established the specialty of medical genetics, and the successful application of
new clinical genetic discoveries in UK was greatly assisted by trained clinical and
laboratory geneticists working metaphorically ‘under one roof ’. A network of
genetic centres was created as a result of initiatives by the Royal College of
Physicians, Royal College of Pathologists and the Department of Health. An
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important example was the Special Medical Development allowing the
introduction of molecular genetics in the NHS.158 Patterns of clinical genetics
services in other European countries were documented by the EU-funded
Concerted Action on Genetic Services in Europe (CAGSE)159 and although, in
Europe, CAGSE found a nucleus of highly trained clinical geneticists, this elite
was numerically incapable of delivering the expanding range of new genetic
procedures. As genetic testing moves into the main stream of healthcare,
physicians and others with little training in genetics increasingly administer and
interpret genetic tests. Most routine antenatal genetic screening is the
responsibility of obstetricians and midwives and, although the speed with which
testing for genetic susceptibility for common disease will be integrated into
clinical care is unknown, public awareness is rapidly increasing demands and
hence the need for professionals’ knowledge of genetics. 
In contrast to the generally satisfactory state of clinical genetics where integrated
genetic centres exist, it was apparent that there was a need for an empirical basis
for assessing current genetic education for primary care and other nonclinical
genetic health professionals providing most of the services. Accordingly, the EU
has funded GenEd (Genetics Education: Improving non-genetics health
professionals’ understanding of genetic testing).160 The object is to find out what
is going on at the moment, what is available, what non-geneticists perceive as
important and then to develop educational and training packages which fit into
the special requirements for each country. GenEd will be the first empirical study
to be conducted in the EU on education needs assessment and education
priorities in genetics among non-genetics healthcare professionals.161
Pembrey: We need to round off. We have moved from specific family testing, to
the broader service issues and so on, but another trend that we have got to, and
it’s picking up a little bit on what Susan Povey said earlier on, about the normal,
looking at normal population structure, normal variation as well, not just serious
genetic disease. That’s also been a part; there’s a history there of the use of genetic
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tests and polymorphisms to look at populations in addition to some of the more
health-related issues. I wondered, Derek, whether there are any comments you
want to make on that, in this general field?
Roberts: A most useful feature of the red cell blood group is the illustration of the
principles of genetics in the classroom. You asked us to go back in time: 
The first achievement that made many subsequent developments and applications
possible was in 1557 by the man whose memorial you can see from the window here,
a couple of miles down the street, when Sir Christopher Wren devised an implement
consisting of a sharpened quill and a bladder attached, and it was this that allowed
intravenous therapy, and it also allowed all the investigations that led to not only our
blood-group knowledge, but also to many of the other genetic variants.162
We have spoken of the pressure from patient groups, and I think this is another
outstanding feature that the blood-group work shows us, that much of the
development of our scientific knowledge, particularly in human genetics, has
been as a result of pressure from somewhere else. I suppose the big pressure was
the Franco–Prussian war, about 1870, when the numerous casualties that
required surgical treatment in the field would have benefited from knowledge of
the blood groups and particularly of campatible and incompatible transfusion.163
Shortly after, about 1875, came the discovery of the serological species
specificity, whereby if blood from one species was introduced into another
species, agglutination developed. This animal incompatibility prompted
Landsteiner in Vienna to carry out his inquiries as to whether differences in
agglutination such as occurred in interspecific mixtures also occurred between
individuals of the same species. This, of course, led him to discover what
subsequently became known as the ABO blood groups in 1900 and the fourth,
the AB group, discovered two years later.164 I suppose also that the widest
application of genetic testing, namely testing for the presence of a genetic
character, is that of the ABO blood groups. Many of us, perhaps not so many
here, a couple of decades ago, or several decades ago, wore round our necks dog
tags with our blood groups, to be of use and application when we required
transfusions. That type of genetic testing was applied to millions of individuals
and has expanded as our knowledge of blood groups developed. 
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One of the most useful applications, not only of the blood groups, but of the
other human polymorphisms, has been the information it has given us on the
lack of homogeneity of human populations. Namely even in an area such as
Britain, if you plot the distribution of the blood-group frequencies, you see that
there are pronounced regional differences in frequency, not only big regional
differences and frequencies, there are also local differences, and these I think are
more and more important as one finds the curious, very rare, genetic conditions
that are associated with the molecular heterogeneity. These too show a
remarkable lack of uniformity, and we want to know why. The differences in
gene frequency between north Northumberland and Tyneside, or between the
different parts of the Lake District, how have these come about? These are of
relevance in a clinical situation, because, for instance, we want to know whether
the curious conglomeration of unpleasant disorders that have occurred round
Sellafield, are the result of some underlying population structure, or whether as
a result of the presence of the British Nuclear Fuels establishment there. I think
we are at the stage of exit of the polymorphisms, the classical polymorphisms,
and the serological polymorphisms, they are being replaced by molecular work.
There we have had the pressure from medicine, but we have also had it from
another curious source, the lawyers, for forensic medicine, as forensic medicine
and its applications of genetic tests, in paternity cases for instance, and the
identification no longer depends on the quite precise probabilities that can be
obtained from testing with a battery of polymorphic markers to be replaced by
the much less time-consuming molecular tests. I don’t think I have very much
else to say on this, I would like to have spoken a little on a completely different
topic, but anyway I have done what you asked me.
Pembrey: We’ve had a full sweep from academic interest in the early blood
groups and so forth, right through to testing, and to delivery of genetic services,
and then back again to the broader polymorphism in the population, which is
going to be essential as we try to tackle complex diseases. I think as we finish, it
would be quite good to get a general feel (I know people might be reluctant to do
this) about the other question that Doris raised in her introduction. Was it just
the individuals, or were there schools or groupings, critical masses of people in
Britain over the last century, that led to the accelerated application of this genetic
knowledge, or the discovery of genetic variation for genetic testing as such? I am
just wondering if anybody wants to comment. Historians like schools, but I am
not sure the people who were involved see it in quite that way. We probably don’t
see it as a school. It sounds like something terribly formal, but just a network, a
zone of collaboration that was critical. Were there such foci of activity?
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Woodrow: Surely there were no rigid rules here. Some years ago it was possible
for a small group of interested people, using relatively unsophisticated
techniques, to make useful and even important contributions. In Liverpool Cyril
Clarke had many of the qualities of the best 19th-century naturalists, and he and
his colleagues were not primarily geneticists. It may be that work of this kind is
no longer possible and all the important work will be done in institutes of the
kind that David Weatherall left Liverpool to set up in Oxford, and in those that
have been established subsequently. 
Ferguson-Smith: I would like to emphasize something that Rodney has just
pointed to, how successful for genetics has been the development of a network
of groups within the UK. That is rather special to the UK. It was made possible
by each of us knowing one another, and deciding on sharing and having
common interests and common meetings. It also occurred in the environment of
the National Health Service, which is absolutely key, and something that is a
tremendous advantage that the UK has, for example, as opposed to North
America and Europe. Some of us were fighting political attempts to destroy this
network in the Thatcher days and fortunately I am happy to say that in politics
the pendulum has swung the other way again, and now we look like developing
and strengthening the network that we have got. I think that’s something special
about genetic services in the UK that bears mentioning. 
Adinolfi: Talking about ‘schools’ or ‘groupings’, I think that we should mention
the ‘critical mass’ of scientists involved in the discoveries of blood-group antigens
here in the UK. I am referring to the work of R R Race, Ruth Sanger, A E
Mourant, W V Watkins, W T J Morgan and P L Mollison, just to mention a few.
Many foreign scientists have learned genetics by visiting blood group units in the
UK, like R Ceppellini and R Grubb who later discovered the relationship
between the Lewis and the Secretor/non-secretor system.164a
About new techniques, the detection of ‘incomplete’ Rh antibodies by the
antiglobulin test by Coombs, Mourant and Race in 1946 solved many problems,
including those associated with maternal–fetal incompatibilities.165
Pembrey: Yes, I think it very much did.
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Booth: This is a question from a complete non-expert, but in Huntington’s
chorea the argument we constantly hear is do you want to genetically screen
members of families; do people want to know they have got the disease long
before they have developed it? That applies to a whole lot of other diseases too,
but let’s take Huntington’s as an example.
Pembrey: There are only a few minutes left and I think that’s another workshop. I
would like to add hat, in addition, it is probably partly because of the size of the
country that this network was manageable to get together. I think the formation of
the Clinical Genetics Society in 1970 was very timely and it is fair to say that there
is a tradition when people are trained in genetics, if a research fellow has a project
and needs cases of a relatively rare kind, there’s a sort of unwritten rule, which I
think still exists and always did exist, of well so and so in this unit is doing it, so we
send everything there. I think the links between the clinicians and the scientists and
this sort of sharing, and I know we are saying it about ourselves, is something that’s
been quite influential in pushing forward the clinical applications of genetic testing.
Harris: I wanted to add and reinforce what you have said and what Malcolm was
saying. We haven’t mentioned Cedric Carter,166 I don’t think, but I think we
ought to, because of his founding of the Clinical Genetics Society. I was at it,
and he made me Treasurer of the Society (and Sarah Bundey was the Secretary –
that’s the beginning). Cedric really midwived that and the Institute of Child
Health had a very large part in this networking, especially when the
dysmorphology thing came along. There’s no question about that at all. 
The other thing that comes from the relationship with the Department of
Health or the DHSS as we used to know and love it,167 was that Cedric, through
the Department of Health, was responsible for getting the job of consultant
clinical geneticist established as part of the Health Service and that allowed the
network to develop. Subsequently, but again through the consultant adviser, the
money came for the molecular genetic laboratory, the three molecular genetic
laboratories you have mentioned before. This really has been a very important
and influential aspect, to a large extent due to Cedric’s Institute initiation.
Pembrey: Yes, I would endorse that. 
Mrs Diane Barnett: As a non-doctor here, I hope you will allow me a couple of
words. I am a representative of a national organization called Contact a Family, and
Genetic Testing (v19)  3/11/03  8:46 pm  Page 69
168 More information about Contact a Family can be found at www.cafamily.org.uk/dirworks.html. 
we act as an umbrella for many, many disorder groups.168 I am wondering whether
– as I know a number of the doctors here know of the disorders I am talking about,
and perhaps know of the groups – whether they feel that these groupings of parents,
sometimes only a very few, ten perhaps, of identified cases and some of them
much larger, whether this has had an influence and helped perhaps in your work?
Pembrey: An enormous influence. Clinical research fellows, certainly speaking
for the Institute of Child Health, if they latched on to a particular condition,
they were interested in a particular condition, they would immediately make
contact and establish a relationship with the support group. Sometimes there was
more than one support group. I know in my own work that I did on Angelman
syndrome; there’s nothing like going to a meeting where there are a hundred
children with Angelman syndrome to never not be able to diagnose it again. So
I think that again has been a feature, and I tried to bring it out in that
neurofibromatosis story. I think it has been a feature in Britain. We have got the
Contact a Family, and then we have the Genetic Interest Group as well, that
produces the appropriate political representation at the Department of Health
and Government.
Rodeck: I think it is relevant to point out that the activity of prenatal screening
and diagnosis is controversial in some areas and there are opponents on ethical
grounds, and indeed the people who are involved in that activity have been
accused of eugenics and of ‘search and destroy’ and that kind of thing. That is in
very sharp contrast to the attitude of most of the patient support groups who, in
my experience, have nearly always welcomed advances in prenatal diagnosis for
the families with their particular conditions, because they see it as simply another
medical facility that is made available to their members.
Povey: I was just going to reiterate about the support groups. For example, in
tuberous sclerosis, the support group there really started out as a smallish group
of articulate parents and that group has been responsible for genetic testing being
ten years ahead of where it would be by their pressure and their support for the
work.
Edwards: It has been brought up several times, but so far we have been
discussing all the recent advances. I wanted to draw attention to a great non-
advance over the last 20 years, which unfortunately has been associated with the
potential for the Internet and that is secrecy. The journals do not insist on raw
data being made available after publication. It’s widely believed that there are
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methods for analysing things with great complexity by methods nobody really
understands, and we now have the multi-author paper. There are two varieties:
those in which a minority of the authors understand it, and those in which none
of the authors understand it. Very few of these authors could have had time to
influence the paper, and I know of some who first read it in print. Peer review is
incomplete, Nature rejects most papers without peer review and, like Science,
often fails to answer letters pointing out factual errors in editorials. The Internet
offers space to resolve the physical problems in making raw data available at
publication, suitably shorn, even at the cost of some information, of any possible
breach of clinical confidentiality.  However only Elsevier enforces this, and, so
far as I know, of the major analysis of human data, only Hinxton and Professor
John Todd make access to raw data simple.168a  Unless those responsible, as
advisers on ethics or purveyors of grants or,  for ensuring blood and gold provide
the maximum information, and insist on this obvious convention, the major
problems of analysis and related optimal strategies in major population studies,
haplotype mapping and multifactorial disorders will remain inadequately
resolved for even longer.
The other point is that there has almost been no conceptual development in the
last 20 years. The development has been technical. The great conceptual
development took place in the 1930s, with people like Wright and Hogben and
so on, but their papers are all lying about in basements and second-hand
bookshops. It does seem very important requirement that 1 per cent of the cost
of putting papers on the Internet should go to the great papers which are few in
number, which are now virtually non-existent, because most people don’t go to
libraries, they go to the Internet and what’s on the Internet is what exists. I think
this is a very important problem, because there has really been very little
conceptual advance in the last 20 years. The advances have all been made in the
past and we can only make use of the great advances of the past if the raw data
are made available, so that they can be analysed and considered. This is
particularly important in the DNA field, because the big advance is going to be
relating to environment, rather than purely to the pharmaceutical industry. 
Pembrey: I think that is a very good point and a message to the Wellcome
History of Medicine Group, that in addition to recording our sometimes
rambling reminiscences and details of how we saw genetic testing develop, they
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may perhaps look to researching the maintenance of raw data, rather than just
anecdotes and the issue of material disappearing after publication as the paper
copies get lost.169 I think it is an area where perhaps, John [Edwards], you might
want to put a project to the History of Medicine people at the Wellcome on this.
But it is certainly relevant to historians as well as to scientists trying to progress.
I should like to thank everybody very much for what has been a long afternoon,
for being so attentive and contributing so well to this Witness Seminar. Thank
you very much.
Christie: I would like to add my particular thanks to Marcus Pembrey for his
excellent chairing of the meeting, and also to Doris Zallen for travelling from the
USA to be with us today.
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Royal Society 1936–1938. London:
Harrison and Sons, 225–228. 
Professor Joseph Goldstein 
(b. 1940) has been Paul J Thomas
Professor of Medicine in the
Department of Molecular Genetics
at the University of Texas
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Southwestern Medical Center at
Dallas since 1977. He shared the
1985 Nobel Prize for Physiology or
Medicine with Michael Brown for
their work on the genetic basis of
hypercholesterolaemia.
Professor John Burdon Sanderson
Haldane 
FRS (1892–1964) was Professor 
of Genetics at University College
London from 1933 to 1937, and
Professor of Biometry at UCL from
1937 to 1957. See Pirie N W.
(1966) John Burdon Sanderson
Haldane FRS. Biographical Memoirs
of Fellows of the Royal Society 12:
219–250. 
Professor Alan Handyside 
(b. 1951) is Professor of
Developmental Biology in the
School of Biology, University 
of Leeds. Influenced by Professor
Robert Edwards while studying at
Cambridge, who was pioneering
human in vitro fertilization in the
mid-to-late 1970s, he became
interested in early mouse
development. He later joined
Professor Lord Robert Winston at
Hammersmith Hospital, London,
where the first pregnancies
following assisted conception and
pre-implantation genetic diagnosis
were established in 1989 in a series
of couples at risk of X-linked
inherited disease.
Professor David Harnden 
FRCPath FRSE (b. 1932) was a
Scientific Member of the Medical
Research Council Radiobiology
Unit, Harwell, from 1957 to 1959,
and a Scientific Member of the
Medical Research Council Clinical
and Population Cytogenetics Unit,
Edinburgh, from 1959 to 1969. He
was Professor of Cancer Studies at
the University of Birmingham
(1969–83) and Honorary Professor
of Experimental Oncology at the
University of Manchester
(1983–97). From 1997 he has been
Chairman of the South Manchester
University Hospitals NHS Trust. 
Professor Peter Harper 
(b. 1939) is Professor of Medical
Genetics at University of Wales
College of Medicine, Cardiff. He
has been closely involved with the
identification of the genes
underlying Huntington’s disease 
and muscular dystrophies, and 
with their application to predictive
genetic testing. He has also been
responsible for the development of 
a more general medical service for
Wales and has a particular interest
in the historical aspects of human
and medical genetics. See Harper 
P S. (1995) Genetic testing,
common diseases and health service
provision. Lancet 346: 1645–1646. 
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Professor Harry Harris
FRCP FRS (1919–94) was Director
of the MRC Human Biochemical
Genetics Unit from its foundation
in 1961 until he left to continue
work in the USA in 1976. From
1965 to 1976, he was Galton
Professor of Genetics and Biometry
at UCL. His extensive laboratory
research into patterns of human
genetic diversity in health and in
disease led to the concept of normal
genetically determined biochemical
variation between different
individuals, and prepared the
ground for many genetic tests
currently widely used today. See
Hopkinson D A. (1996) Harry
Harris FRS. Biographical Memoirs 
of Fellows of the Royal Society 42:
152–170.
Professor Sir Henry Harris 
FRCP FRCPath FRS (b. 1925) was
Professor of Pathology at University
of Oxford from 1963 to 1979, and
Head of Department in the Sir
William Dunn School of Pathology,
Oxford,  from 1963 to 1994. See
Harris H. (1993) How tumour
suppressor genes were discovered.
FASEB Journal 10: 978–979.
Professor Rodney Harris 
CBE FRCP FRCPath (b. 1932) 
is Emeritus Professor of Medical
Genetics at the University of
Manchester having been Professor
of Medical Genetics from 1980 to
1997. From 1982 to 1989 he was
Consultant Adviser in Medical
Genetics to the Chief Medical
Officer at the Department of
Health. He was Chairman of the
UK National Confidential Inquiry
into Genetic Counselling from
1986 to 1990, Chairman of the
Royal College of Physicians of
London Committee on Clinical
Genetics and subsequently
Chairman of the EU concerted
Action on Genetic Services in
Europe. He is now Coordinator 
of the EU-funded GenEd measure. 
Professor Lancelot Hogben 
FRS (1895–1975) was Regius
Professor of Natural History at the
University of Aberdeen from 1937
to 1941 and from 1941 to 1947
was Mason Professor of Zoology at
the University of Birmingham, later
Professor of Medical Statistics from
1947 to 1961. See Wells G P. (1978)
Lancelot Thomas Hogben FRS.
Biographical Memoirs of Fellows of the
Royal Society 24: 183–222.
Mrs Cathy Holding (Previously
Headhouse-Benson.)
(b. 1957) is a research assistant
currently at the Babraham Institute
in Cambridge, UK. She has worked
with Professor Marilyn Monk three
times during the last 20 years, once
at the MRC Mammalian
Development Unit, and twice at the
Institute of Child Health in London.
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Professor Martin Hooper 
FRSE FRCPE (b. 1947) was a
research fellow in the Institute of
Genetics, University of Glasgow,
from 1973 to 1980. In 1980 he
moved to the University of
Edinburgh, where he has been
Senior Lecturer in Experimental
Pathology (1980–90), Reader in 
the Department of Pathology
(1990–96) and Professor of
Molecular Pathology since 1996.
Professor David Hopkinson 
(b. 1935) was Director of the
Medical Research Council Human
Biochemical Genetics Unit from
1976 to 2000. Since 1993 he 
has been Professor of Human
Biochemical Genetics at University
College London. 
Professor Sir Douglas Hubble 
KBE FRCP (1900–81) was
Professor of Paediatrics and Child
Health and Director of the Institute
of Child Health at the University 
of Birmingham from 1958 to 1968.
See Wolstenholme G. (1984) Sir
Douglas Vernon Hubble. Munk’s
Roll 7: 280–281. 
Professor Vernon Ingram 
FRS (b. 1924) has been Professor 
of Biochemistry since 1961 at the
Massachusetts Institute of Technology,
Boston, USA, and John and
Dorothy Wilson Professor of
Biology since 1988. 
Professor Patricia Jacobs 
OBE FRSE FRCPath FRCPE
FRCOG FRS (b. 1934) was a
Medical Research Council scientist
(1957–72), Professor in the
Department of Anatomy and
Reproductive Biology at the
University of Hawaii School of
Medicine (1988–2001), Professor
and Chief of the Division of
Human Genetics in the Department
of Paediatrics at Cornell University
Medical College (1985–87) and
Director of the Wessex Regional
Genetics Laboratory (1988–2001). 
Professor Yuet Wai Kan 
FRCP FRS (b. 1936) was Associate
Professor of Pediatrics at Harvard
Medical School from 1970 to 1972
and was Associate Professor of
Medicine in the Departments of
Medicine and Laboratory Medicine
at the University of California, 
San Francisco from 1972 to 1977.
Since 1977 he has been Professor of
Laboratory Medicine and Medicine
at the University of California.
Professor Herman Lehmann 
CBE FRCP FRCPath FRSC FRS
(1910–85) was Professor of Clinical
Biochemistry at the University of
Cambridge from 1967 to 1977, and
Honorary Director of the Medical
Research Council Abnormal
Haemoglobin Unit from 1963 to
1975. See Dacie J. (1988) Herman
Lehmann FRS. Biographical
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Memoirs of Fellows of the Royal
Society 34: 405–450. 
Dr Mary Lyon 
FRS (b. 1925) was on the scientific
staff of the Medical Research
Council Radiobiology Unit, Harwell,
from 1955 to 1990 and Deputy
Director of the Unit from 1982.
Sir John Maddox 
Kt HonFRS (b. 1925) was Lecturer
on Theoretical Physics at University
of Manchester (1949–55), Science
Correspondent of the Guardian
(1955–64) and Editor of Nature
(1966–73, 1980–95). 
Professor Sue Malcolm 
FRCPath was Professor of
Molecular Genetics, at the Institute
of Child Health, London, until
June 2002, now Emeritus.
Professor Thomas McKeown 
FRCP (1912–88) was Professor of
Social Medicine at the University 
of Birmingham from 1945 to 1977.
See Wolstenholme G. (ed.) (1989)
Thomas McKeown. Munk’s Roll 8:
311–313. 
Dame Anne McLaren 
DBE FRCOG FMedSci FRS 
(b. 1927) was the Director of 
the Medical Research Council’s
Mammalian Development Unit,
University College London, from
1974 to 1992, and was Fullerian
Professor of Physiology at the Royal
Institution from 1990 to 1995.
Sir Peter Medawar 
OM CH CBE FRS (1915–87) was
Jodrell Professor of Zoology and
Comparative Anatomy at University
College London from 1951 to
1962. He shared the 1960 Nobel
Prize in Physiology or Medicine
with Macfarlane Burnet for the
discovery of immunological
tolerance. Between 1962 and 1971
he was Director of the National
Institute for Medical Research at
Mill Hill, London, remaining on 
its scientific staff until 1984. See
Mitchinson N A. (1990). Peter
Brian Medawar FRS. Biographical
Memoirs of  Fellows of the Royal
Society 35: 281–302.
Professor Reuben Mibashan 
FRCP FRCPath (1927–2001) 
held posts in the Department 
of Medicine at the Cape Town
University Medical School.
Following research fellowships 
in London and Salt Lake City, 
he settled in the UK and was
appointed Professor of Haematology
at King’s College School of
Medicine in 1986. See Anon.
(2001) R S Mibashan. Proceedings
of the Royal College of Physicians 
of Edinburgh 31: 269.
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Professor Ursula Mittwoch 
DSc (b.1924) entered the Galton
Laboratory as a PhD student in
1947. She was later offered
postdoctoral appointments to work
on the biochemistry of cystinuria
(in collaboration with Harry Harris
and Bette Robson), and on
cytogenetics. During the 1960s 
she carried out genetic testing by
demonstrating mucopolysaccharide
inclusions in the lymphocytes of
patient with Hurler and Hunter
syndromes. Since then she has
specialized in the genetics of sex
determination with special reference
to cell proliferation. In 1989 she
retired as Emeritus Professor.
Professor Bernadette Modell 
FRCP FRCOG (b. 1935) is
Emeritus Professor of Community
Genetics in the Department of Health
Informatics and Multiprofessional
Education (CHIME) at the Royal
Free and University College Medical
School, London. 
Professor Patrick Mollison
CBE FRCP FRCPath FRCOG FRS
(b. 1914) was Professor of
Haematology at St Mary’s Hospital
Medical School, University of
London, from 1962 to 1979, then
Professor Emeritus and Honorary
Consultant Haematologist at the
London Blood Transfusion Service
from 1983.
Professor Walter Morgan
CBE FRS (1900–2003) was
Professor of Medicine at the Lister
Institute of Preventative Medicine,
University of London, from 1951 to
1968, then Professor Emeritus, and
Director of the Lister Institute from
1972 to 1975. See Tippett P. (2003)
Professor Walter Morgan. Vox
Sanguinis 84: 161–162. Anon.
(2003) Professor Walter Morgan.
Daily Telegraph, 14 February 2003,
page 14. 
Dr Arthur Ernest Mourant
FRCP FRCPath FRS (1904–94)
was Physician, and Director of the
Blood Group Reference Laboratory,
Lister Institute. In 1944 he
discovered the predicted antibody,
anti-e, helping to establish the
three-factor theory of the Rhesus
system. His published works include
The Distribution of the Human
Blood Groups (1954); The ABO
Blood Groups and Maps of World
Distribution (1958).  See Misson 
G P, Bishop A C, Watkins W M.
(1999) Arthur Ernest Mourant.
Biographical Memoirs of Fellows 
of the Royal Society 45: 331–348.
Professor Linus Pauling 
(1901–94) was Professor of
Chemistry at the California
Institute of Technology (1931–
1963) and from 1974 was Research
Professor at the Linus Pauling
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Institute of Science and Medicine.
He was awarded the 1954 Nobel
Prize for Chemistry, and the 1962
and 1963 Nobel Peace Prize.
Professor Marcus Pembrey 
FRCP FRCPCH FRCOG FMedSci
(b. 1943) was Head of the
Mothercare Unit of Paediatric
Genetics at the Institute of Child
Health and Consultant Clinical
Geneticist at the Hospital for Sick
Children, Great Ormond Street,
London, from 1979 to 1998. 
He was Consultant Adviser in
Genetics to the Chief Medical
Officer, Department of Health 
from 1989 to 1998. After training
in medical genetics at Liverpool and
Guy’s Hospital, he led a team that
helped to introduce DNA testing
into clinical genetics in the 1980s
and carries out research into 
non-Mendelian inheritance. 
Professor Lionel Sharples Penrose 
FRCP FRS (1898–1972) was
Resident Director of the Royal
Eastern Counties Institution,
Colchester, from 1930 to 1939. 
He was Galton Professor of
Eugenics from 1945 to 1962, 
and of Human Genetics from 
1962 to 1965, at University College
London. See Harris H. (1973).
Lionel Sharples Penrose FRS.
Biographical Memoirs of Fellows 
of the Royal Society 19: 521–562. 
Professor Naomi Pfeffer 
(b. 1946) is Historian of Medicine
at London Metropolitan University.
Professor Paul Polani 
FRCP HonFRCP(Ire) FRCPCH
FRCOG HonFRCPath DCH FRS
(b. 1914) is Fellow of King’s College
London, and Geneticist, Division of
Genetics and Development at Guy’s
Hospital, Research Professor
Emeritus, London University
(1982), Prince Philip Professor 
of Paediatric Research at Guy’s
Hospital Medical School, and
Director of Paediatric Research Unit
there (renamed Division of Genetics
and Development, King’s College,
London) (1960–82), Geneticist,
Guy’s Hospital and Medical School,
and Director of South East Thames
Genetics Centre (1976–82) and
Honorary Paediatrician, Guy’s
Hospital and Medical School
(1960–85).
Professor Bruce Ponder 
FRCP FRCPath FMedSci FRS 
(b. 1944) has been Honorary
Consultant Physician at the Royal
Marsden Hospital, London, since
1980, and Director of the Cancer
Research UK Human Cancer
Genetics Group at the University 
of Cambridge since 1989.
Professor Sue Povey 
FMedSci (b. 1942) qualified in
medicine from Cambridge/UCH in
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1967, studying genetics under 
J M Thoday and Harry Harris.
After a brief period in paediatrics 
at University College London and
in north Africa, she worked for the
MRC Human Biochemical Genetics
Unit at the Galton Laboratory
(1970–2000) and was appointed
Haldane Professor of Human
Genetics at UCL in 2000. She has
had a long-term interest in human
gene mapping and positional
cloning. As Chair of the Human
Gene Nomenclature Committee 
she is currently trying to provide 
a single approved name for every
human gene. 
Dr Robert Race
CBE FRS (1907–84) was Director
of the Medical Research Council
Blood Group Unit from 1946 to
1973. See Clarke Sir C. (1985)
Robert Russell Race. Biographical
Memoirs of Fellows of the Royal
Society 31: 455–492.
Professor Derek Roberts 
FRSE (b. 1925) was Professor of
Human Genetics at the University
of Newcastle upon Tyne and
Honorary Consultant to the Royal
Victoria Infirmary, Newcastle upon
Tyne, Honorary Director, Genetic
Advisory Service NHS Northern
Region from 1965 to 1990,
Professor Emeritus since 1990.  
Professor Charles Rodeck 
FRCOG FRCPath FMedSci 
(b. 1944) is Professor of Obstetrics
and Gynaecology and Head of
Department at University College
London, and Director of the Fetal
Medicine Unit at University College
London Hospitals. His research and
clinical practice have been in
prenatal diagnosis and the emerging
discipline of fetal medicine. He
established the first fetal medicine
unit in the UK in 1983, the Harris
Birthright Centre at King’s College
Hospital, and further departments 
of fetal medicine at Queen
Charlotte’s Maternity Hospital
(1986), and University College
Hospital (1990). He has been
President of the International Society
for Prenatal Diagnosis since 2002.
Dr Ruth Sanger
FRS (1918–2001) was on the
Scientific Staff of the Medical
Research Council Blood Group
Unit from 1946 to 1983, and was
Director of the Unit from 1973 to
1983. See Mollison P L. (2002)
Ruth Sanger. Transfusion 42:
125–126.
Dr Alan Stevenson 
CBE FRCP (1909–95) was the
Director of the Medical Research
Council Population Genetics Unit,
Oxford, and Lecturer in Human
Genetics at the University of
Oxford from 1958 to 1974. 
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See Gillam S J, Macdonald I. (eds)
(2001) Alan Carruth Stevenson.
Munk’s Roll 10: 469–470.
Dr Patricia Tippett 
(b. 1930) was a member of the
Medical Research Council Blood
Group Unit from 1958 to 1995 and
became Director of the Unit when
Ruth Sanger retired in 1983. 
Professor John Todd 
(b. 1958) has been Professor of
Medical Genetics and a Fellow 
of Gonville and Caius College,
Cambridge, since 1998. 
Professor Edward (Ted)
Tuddenham 
FRCP FRCPath (b. 1944) was 
Co-director of the Haemophilia
Centre, The Royal Free Hospital,
London, from 1978 to 1986, and
Director of the Medical Research
Council Haemostasis Research
Group at Northwick Park Clinical
Research Centre from 1987 to 1994.
He has been Director of the
Haemostasis Research Group,
Clinical Sciences Centre, Imperial
College Medical School, London,
since 1994 and Honorary Consultant
Haematologist at the Hammersmith
Hospital, London, since 1994. He is
a member of the World Federation of
Hemophilia, the International Society
on Thrombosis and Hemostasis, and
the British Society of Haemostasis
and Thrombosis.
Dr David Tyrrell 
FRS (b. 1925) was a member of 
the scientific staff of the Medical
Research Council Common Cold
Unit at Salisbury from 1957, and 
its Director from 1982 until his
retirement in 1990. His main line
of research was on virus infections
in humans.
Mr (Richard) Humphry Ward 
FRCOG (b. 1938) was Consultant
Obstetrician and Gynaecologist at
University College London, from
1972 to 2001. 
Dr Winifred Watkins
FMedSci FRS (b. 1924) was
Professor of Biochemistry at the
University of London from 1968 
to 1975. Since 1990 she has been
Visiting Professor and Senior
Research Fellow at the Imperial
College School of Medicine, London.
Professor Sir David Weatherall 
Kt FRCP FRCPE FRS (b. 1933)
was Professor of Haematology at the
University of Liverpool from 1971
to 1974, and Nuffield Professor of
Clinical Medicine at the University
of Oxford from 1974 to 1992.
From 1992 to 2000 he was Regius
Professor of Medicine at the
University of Oxford and Honorary
Director of the Molecular
Haematology Unit of the Medical
Research Council (1980–2000) 
and the Institute for Molecular
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Medicine (1988–2000; later the
Weatherall Institute of Molecular
Medicine, 2000). 
Professor Robert (Bob)
Williamson 
FRCP FRCPath FRS (b. 1938) 
was Professor of Biochemistry at 
St Mary’s Hospital Medical School,
London, from 1976 to 1995 and
from 1995 has been the Director 
of the Murdoch Children’s Research
Institute, Royal Children’s Hospital,
Melbourne, and Research Professor
of Medical Genetics at the University
of Melbourne School of Medicine.
Professor Lord Robert Maurice
Winston 
Baron Winston of Hammersmith
FRCOG FRCP (b. 1940) has been
Consultant Obstetrician and
Gynaecologist at the Hammersmith
Hospital, London, since 1978, 
and Professor of Fertility Studies 
at Imperial College School of
Medicine, London, since 1987. 
He has presented numerous
television series discussing medicine
and the human body, including 
The Human Body (BBC TV, 1998)
and Superhuman (BBC TV, 2000). 
Professor John Woodrow 
FRCP (b. 1924) was on the staff 
of the Department of Medicine at
the University of Liverpool between
1961 and 1991, and was
Consultant Physician (General
Medicine and Rheumatology) to 
the Liverpool United Hospitals. 
Mrs Elisabeth Young 
(b. 1942) worked in the Enzyme
Laboratory, Department of
Chemical Pathology, Hospital 
for Sick Children, Great Ormond
Street, London, since 1968. She 
has been a principal biochemist
since 1990.
Professor Doris Zallen 
(b. 1941) is Professor of Science 
and Technology Studies at Virginia
Polytechnic Institute and State
University in Blacksburg, Virginia.
A former laboratory scientist who
has made contributions to cell
biology and linkage testing, she 
now conducts research on the
ethical, social  and policy issues
related to genetic testing and other
clinical uses of genetics.
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Adenosine deaminase (ADA)
deficiency
A severe immunodeficiency disease
that results from a lack of adenosine
deaminase and usually leads to death
within the first few months of life.
Now amenable to gene therapy. 
Alkaptonuria
An autosomal recessive disorder,
the first to be described in humans,
caused by the lack of homogentisate
1,2 dioxygenase. It may result in
arthritis of the spine and joints, 
and kidney stones.
Allele
An alternative chemical variant of a
given gene at its locus. There may
be, for that gene, a number of alleles.
Amniocentesis
The sampling of amniotic fluid by
inserting a needle into the womb,
usually at 14–16 weeks’ gestation
allowing diagnostic tests on the
fluid, chromosomal analysis and
other tests on cultured or
noncultured cells. It may be safer
than chorionic villus sampling
(CVS) but has to be done later and
results usually take longer.
Anencephaly
The absence of most of the brain 
in the fetus: a common cause of
stillbirth.
Aneuploidy
Having a variant chromosome
number (too many or too few) 
that is neither the haploid number
nor a simple multiple there of 
(e.g. Down’s syndrome, Turner
syndrome).
Angelman syndrome
A condition characterized by severe
mental deficiency, developmental
delay and dwarfism, puppet-like
gait and frequent inappropriate
laughter.
Autosomal recessive disorder
A disorder caused by an error or
mutation in a single unit of genetic
information. An autosomal disorder
that is recessive can be expressed in
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a person only if both copies 
of the gene are altered. Examples
include cystic fibrosis and
Tay–Sachs disease.
Autosome
Any chromosome other than the sex
chromosome. In humans, there are 46
chromosomes, 22 pairs of autosomes
and either two Xs or an X and a Y.
Barr body
Densely staining nuclear mass seen
in the somatic nuclei of mammalian
females.
Base pair
A pair of hydrogen-bonded
nitrogenous bases (one purine and
one pyrimidine) that join the two
strands of the double helix.
Batten’s disease
A group of severe progressive
neurodegenerative disorders.
Becker muscular dystrophy
See Duchenne muscular dystrophy.
Carrier
An unaffected person who harbours
a disease gene.
CAH
See congenital adrenal hyperplasia.
Chiasma
The region of contact between
homologous chromosomes during
meiosis. 
Chorionic villus sampling (CVS) 
A diagnostic procedure involving
removal of villi from the human
chorion to obtain cells for diagnosis
of  chromosomal and some
metabolic disorders in early
pregnancy.
Chromatin
The readily stainable portion of a
cell nucleus consisting of DNA and
RNA, and various proteins.
Chromosomal mosaicism
The existence of cells with two or
more chromosomal variants within
one individual due to events after
fertilization.
Chromosome
The self-replicating genetic
structures of cells containing the
DNA that bears the gene sequence.
Humans have 23 pairs of
chromosomes, 46 in all: 44
autosomes and two sex
chromosomes. Each parent
contributes one chromosome to
each pair, so children get half of
their chromosomes from their
mothers and half from their fathers.
Chronic myeloid leukaemia
A form of leukaemia characterized
by uncontrolled proliferation of
myeloid cells in the bone marrow
and in other sites, and the presence
of large numbers of immature and
mature granulocytic forms in
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various tissues and blood. Also
referred to as chronic granulocytic
leukaemia.
Codominancy
Pertaining to a pair of dissimilar
alleles that are both expressed when
present together at a particular
locus, the individual being a
heterozygote at that locus.
Codon (triplet code)
A specific sequence of three
consecutive bases that is part of the
genetic code and that specifies a
particular amino acid in the
synthesis of protein or starts or
stops such synthesis. 
Colchicine
An alkaloid that blocks mitosis. 
Congenital adrenal hyperplasia
(CAH)
A form of adrenal insufficiency due
to mutations in genes coding for
enzymes needed by the adrenal
cortex. About 95 per cent of cases
of CAH are caused by absence of 
21-hydroxylase, which is necessary
for efficient production of cortisol
and aldosterone. 
CVS 
See chorionic villus sampling.
Cystic fibrosis
An inherited recessive disorder
characterized by chronic infections
of the respiratory tract, liver disease
and digestive problems.
Cytogenetics
The study of cells, and especially
their chromosomes.
Cytotrophoblast
See trophoblast.
Deletion
The loss of a piece of DNA from 
a chromosome that may lead to a
disease or abnormality. A synonym
of the term ‘deficiency’.
Diploid
The presence of the two haploid
sets, one from each gamete, of
chromosomes in a cell.
Disjunction
The separation of chromosomes
during cell division.
Down’s syndrome (trisomy 21,
mongolism)
One of the most common causes of
mental retardation, due to trisomy
of chromosome 21. See Lejeune et
al. (1959). 
Duchenne muscular dystrophy
An X-linked recessive disorder
caused by a mutation, usually a
deletion, in the gene for dystrophin,
a protein essential for muscle after
infancy. A similar but milder
condition known as Becker muscular
dystrophy is caused by different
mutations in the same gene.
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Duplication
A chromosomal aberration in which
a segment of chromosome is
duplicated.
Electrophoresis
A technique used to separate 
a mixture of molecules by their
differential migration through 
a gel in an electrical field.
Eugenics
The study of methods of improving
genetic qualities by selective
breeding.
Factor VIII (antihaemophilic
globulin)
A plasma coagulation factor whose
inherited deficiency is responsible
for haemophilia.
Fluorescent in situ hybridization
(FISH)
A process that vividly paints
chromosomes or portions of
chromosomes with fluorescent
molecules via DNA and may be
used for identifying subtle
chromosomal abnormalities and in
gene mapping.
Fragile site
A heritable gap or nonstaining
region of a chromosome that can be
induced to generate chromosome
breaks.
Fragile X syndrome
A syndrome characterized by mental
retardation, autistic-like behaviour
and other physical abnormalities.
Both males and females can be
affected and their karyotype shows a
gap (the fragile site) on the long arm
of the X chromosome.
Gamete
Specialized reproductive cell, either
sperm or ovum, with a haploid
number of chromosomes. 
Gene
The fundamental unit of heredity. 
A locus defines the position of a
gene.
Genetic marker
A segment of DNA on a
chromosome whose inheritance can
be followed. A marker can be a gene
or some segment of DNA.
Genetic screening
Testing a population group to
identify a subset of individuals at
high risk for having or transmitting
a specific genetic disorder.
Genetic testing
Analysing an individual’s genetic
material to determine predisposition
to a particular disorder, to confirm a
diagnosis or to establish or exclude
identity or paternity.
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Genome
The total set of genes carried by an
individual or cell.
Haemophilia
An X-linked recessive disorder in
which the ability of the blood to
clot is greatly reduced.
Haemopoiesis
The process of producing cellular
constituents of the blood (e.g. red
blood cells, platelets, white blood
cells – mainly lymphocytes and
granulocytes). In adults, haemopoiesis
occurs almost entirely in bone
marrow. In the fetus it also occurs
in the yolk sac, liver, spleen and
thymus.
Hair root test
A test based on the collection of a
certain number of pulled hair roots,
each containing a ‘clone’ of identical
cells. When retrieved from a female
donor, each hair root will have cells
with the same X chromosomes, one
active the other inactive. If a mother
is a carrier of an X-linked disorder,
like the Hunter mutation, one set
of hair roots will contain the
enzyme, the other set will be
deficient.
Haploid
A cell, or occasionally an organism,
having a single set of unpaired
chromosomes. See gamete.
Haplotype
The set of alleles from closely
linked loci carried by an individual
and inherited as a unit until broken
by recombination. See gamete.
Heterozygous
Possessing two different forms
(alleles) of a particular gene, 
one from each parent.
Human leukocyte antigen (HLA)
Cell surface proteins involved in the
acceptance or rejection of cells and
tissues from other individuals.
Human Genome Project (formerly
Human Genome Initiative)
An international research project 
to map each human gene and to
sequence human DNA. 
Huntington’s disease
A degenerative brain disorder that
usually appears in mid-life. Its
symptoms include involuntary
movement of the face and limbs,
mood swings and dementia. It is
generally fatal within 20 years.
Karyotype
The chromosomal complement of
an individual, including the number
of chromosomes and any
abnormalities.
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Klinefelter syndrome 
An endocrine condition in males
caused by the presence of an extra 
X chromosome (47, XXY),
characterized by small testes,
absence of germ cells and low
testosterone level. 
Lesch–Nyhan syndrome
An inborn error of purine
metabolism resulting in severe
neurological problems, renal stones
and self mutilation.
Linkage
The inherited association of certain
genes due to their being localized in
the same chromosome or nucleic
acid molecule.
Lod score
A statistical method used to
determine the relative odds of two
loci being linked or unlinked. 
Lutheran blood group
A blood group inherited
independently of the ABO, 
MN and Rh systems.
Lyon hypothesis
The random inactivation of the
maternal or paternal X chromosome
in somatic cells of mammalian
females early in development. 
All daughter cells will have the 
same X chromosome inactivated,
producing a mosaic pattern 
of expression of genes on the 
X chromosome.
Meiosis
The process of two consecutive cell
divisions with only a single round of
chromosome duplication. Meiosis
results in four rather than two
daughter cells, each with a haploid
set of chromosomes, although ova
only become haploid for maternal
chromosomes after fertilization. 
At meiosis the paternal and
maternal chromosomes cross over,
and most chromosomes are mixed
in terms of parentage.
Metaphase
A stage in mitosis or meiosis during
which the chromosomes are aligned
along the equatorial plane, the ideal
time for their laboratory examination.
Mitosis
The process of nuclear division
followed by cell division and
preceded by chromosome
duplication and separation. Mitosis
results in two daughter cells that are
genetically identical to each other. 
Murine
Mammals of the genus Mus ;
includes rodents (e.g. mice), 
but not hamsters or guinea-pigs.
Mutation
An alteration in DNA or
chromosome structure that can
cause a disorder or inherited
susceptibility to a disorder.
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Nail-patella syndrome
A rare genetic disorder with
abnormalities of the fingernails and
some bones, especially the knee-cap.
Neurofibromatosis
A progressive disorder in which
tumours form on nervous tissue.
These can be severely disfiguring
and can result in loss of vision,
epilepsy, bone deformities, and
learning disabilities
Nucleotide
A structural component, or building
block, of DNA and RNA. 
A nucleotide consists of a base
(adenine, guanine, thymine, or
cytosine in DNA; adenine, guanine,
uracil, or cytosine in RNA),  a sugar
molecule (deoxyribose in DNA and
ribose in RNA) and a phosphate
group. Long chains of nucleotides
make up nucleic acids (DNA or
RNA).
PCR
See polymerase chain reaction.
Phenotype
The observable features of an
organism that results from the
interaction of genes and the
environment.
Phenylketonuria (PKU)
A recessive disorder in humans
associated with the inability to
metabolize phenylalanine, usually
due to absence of phenylalanine
hydroxylase, which results in the
accumulation of phenylalanine in
the blood and impairs early
neuronal development. The
condition can be controlled by diet.
Phytohaemagglutinin
A substance produced by a plant
that agglutinates red blood cells.
Some, including scarlet runner and
American black-eye beans, also
induce cell division in lymphocytes,
the basis of all chromosome analyses
conducted on blood.
PKU
See phenylketonuria.
Polar body
Very small cells produced by grossly
unequal division of the ovum,
allowing one of the four potential
daughter cells to have almost all 
the cytoplasm – the others die. 
Polycystic kidney disease
A group of conditions characterized
by fluid-filled sacs that slowly
develop in both kidneys, eventually
resulting in malfunction.
Polymerase chain reaction (PCR)
A fast, inexpensive technique for
making an unlimited number of
copies of any piece of DNA.
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Polymorphism
Now frequently used as a synonym
for ‘variant’ by molecular geneticists
to cover one or more genes, or
other structures, at the same place
or locus.
Quantitative fluorescent-
polymerase chain reaction 
(QF-PCR)
A highly specific analytical form of
PCR. The QF-PCR assay can be
used for the rapid prenatal diagnosis
of chromosome disorders and the
detection of some single-gene defects.
Restriction enzyme (Restriction
endonuclease)
A bacterial enzyme that recognizes
specific nucleotide sequences in a
DNA molecule and cleaves or nicks
the DNA at that site. Also known as
a restriction endonuclease.
Restriction fragment length
polymorphisms (RFLPs)
Variation in the length of DNA
fragments generated by a restriction
endonuclease. These variations are
caused by enzymes that cut, or do
not cut, specific sequences of DNA. 
Retinoblastoma
A cancer of the retina of the eye.
Usually presenting in childhood:
about half are inherited, the
remainder new mutations.
RFLP
See restriction fragment length
polymorphisms.
Severe combined
immunodeficiency disease (SCID)
A primary immune deficiency, the
defining characteristic being a severe
defect in both the T- and B-
lymphocyte systems. This usually
results in the onset of one or more
serious infections within the first
few months of life. 
Sickle-cell disease
A hereditary form of severe anaemia
due to changes in the structure of
haemoglobin, which causes the red
blood cells to become sickle shaped
in conditions of lowered oxygen.
The sickle-shaped cells block blood
vessels and cut off the blood supply.
Somatic cells
All cells other than the germ cells
and the gametes they produce.
Spermatogenesis
Mitotic and meiotic cell divisions
leading to the production of sperm
cells (spermatozoa).
Swyer syndrome
The condition of complete gonadal
dysgenesis, where the gonads (testes or
ovaries) do not form in the usual way.
It occurs during the first few weeks of
pregnancy. Girls with Swyer syndrome
have XY (usual male) genes.
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Tay–Sachs disease
A fatal degenerative disease of the
nervous system due to a deficiency
of hexosaminidase A, causing
mental deficiency, paralysis and
blindness; found primarily but not
exclusively among Ashkenazi Jews.
Autosomal recessive.
Telomere
The ends of a chromosome
involved in chromosomal stability.
Thalassaemia
Recessively inherited disorder in
which there is an abnormality in
either of the haemoglobin genes.
Transcription
Transfer of genetic information
from DNA by the synthesis of an
RNA molecule copied from a DNA
template.
Translocation
The breakage and removal of a large
segment of DNA from one
chromosome, followed by the
segment's attachment to a different
chromosome.
Triplet code
See codon.
Trisomy
The condition in which a cell or
organism possess three copies of one
chromosome, for example Down’s
syndrome (trisomy 21). Each cell
usually has 46 (i.e. two copies of
each) chromosomes, but in trisomy
there are 47.
Trophoblast
The outer layer of cells of the
mammalian blastocyst that gives rise
to the placenta. The trophoblast
develops into two layers. The inner
is called the cytotrophoblast.
Turner syndrome
A condition in human females
caused by lack of a second sex
chromosome: 45,X or XO. Such
individuals are phenotypically
female, short and usually sterile
through underdeveloped ovaries.
X inactivation
In mammalian females, the random
cessation of transcriptional activity
of one X chromosome.
X-linked recessive disorders
Disorders due to a mutation on the
X chromosome, usually only
affecting males, but can be
transmitted through healthy female
carriers (e.g. haemophilia, X-SCID
and muscular dystrophy).
Genetic Testing – Glossary
113
Genetic Testing (v19)  3/11/03  8:46 pm  Page 113
Genetic Testing (v19)  3/11/03  8:46 pm  Page 114
ABO blood group, 24, 26, 27, 66
aborted fetuses, 20
abortions
induced, see termination of
pregnancy
spontaneous, 21–22
adenosine deaminase (ADA) deficiency,
42, 59, 105
admixture text, 25
adrenogenital syndrome, 15
agglutination, 66
agriculture, 4, 6
alkaptonuria, 38, 42, 43, 105
allele, 27, 30, 105, 107
allelic association, 27
amniocentesis, 45, 48, 52, 105
amniotic cells
cytogenetics, 19, 20, 50
enzyme assays, 39–40
amniotic fluid, metabolites in, 40
anencephaly, 56, 105
aneuploidy (numerical chromosomal
disorders), 25, 105
diagnostic testing, 23
prenatal diagnosis, 50
see also Down’s syndrome; Klinefelter
syndrome; Turner syndrome
Angelman syndrome, 70, 105
animals
bovine animals, 55
cats, 15, 16
embryo research, 55–56
farm, 4, 6
murine, 8, 110
research using, 61
Ann Arbor, Michigan, USA, 27
Annals of Eugenics (now Annals of
Human Genetics), 20, 29
Anshan Iron and Steel Company
Teaching Hospital, Anshan, China, 47
antiglobulin test (Coombs test), 14, 68
antihaemophilic globulin (factor VIII),
38, 101
Archives of Diseases of Childhood, 31
assisted reproduction, 54, 57
association studies, 27, 30, 32
population, 28–30
Austria, 50
autopsy material, 19
autosomal recessive disorders, 41, 105–106
see also alkaptonuria, Tay–Sachs disease
autosome, 21, 33, 99, 106
Baltimore, Maryland, USA, 12, 13
banding, chromosome, 7, 10, 22
Barr body, 15, 48, 56, 106
Bart’s, see St Bartholomew's Hospital
base pair, 106
Batten’s disease, 39, 106
Becker muscular dystrophy, 10, 34, 106
Berlin, Germany, 53
biochemical genetics, 37, 38–43
pre-implantation diagnosis, 55, 56–57
prenatal diagnosis, 52
Biographical Memoirs of Fellows of the
Royal Society, 43
biopsy
embryo, 56–57, 58
fetal, 47
polar body, 60
tissue, 17, 20, 21, 39, 40, 59
biotinylated probes, 22–23, 62
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Birmingham, 18, 19, 31
blastocyst, 57, 58
blood, peripheral
diagnostic tests, 19, 39
fetal cells in maternal, 50–51
lymphocytes, 4, 18
blood culture, 18, 19
blood groups, 4, 43, 63, 66–67
discovery, 14, 66, 68
disease associations, 24–25, 28
blood transfusion, 14, 43, 66
bone marrow, 17
Boston, Massachusetts, USA, 12,
36–37, 44
brain biopsy, 39
British Nuclear Fuels, 67
buccal smears, 19
CAGSE (Concerted Action on Genetic
Services in Europe), 65
CAH, see congenital adrenal
hyperplasia
California, USA, 53, 64
Cambridge, 4, 13, 24, 34, 55, 56
Cambridge Eugenics Society, 26
Canada, 15, 16, 21–22
cancer, 9–10, 57
-predisposing genes, 63
carbamyl phosphate synthase
deficiency, 40
Cardiff, 33, 35, 42
cardiopathies, congenital, 15
carrier, 106
detection, 14, 31, 40–41, 42, 43–44
misdiagnosis, 41
cataracts, 25
Cell, 32–33
cell culture, 21, 39
cell fusion studies, 8–9
centromeric probes, 23
chiasma, 11, 100
childhood cancers, 9
Children’s Hospital, Philadelphia,
Pennsylvania, USA 19
China, 47, 48, 51, 52
chorionic villi, cytogenetic analysis, 47, 52
chorionic villus sampling (CVS), 58, 106
development, 46, 47–49, 50–51
metabolic disorders, 40, 52, 59
mutational analysis, 40
chromatin, 106
see also sex chromatin
chromosomal abnormalities, 7, 16
diagnostic testing, 15, 18–21, 23
in malignancy, 9–10
numerical, see aneuploidy
pre-implantation diagnosis, 62–63
prenatal diagnosis, 49–50
sex, 7, 25
in spontaneous abortions, 21–22
subtelomeric rearrangements, 10
see also deletions; translocations
chromosomal mosaicism, 8, 106
chromosome(s), 6–11, 106
banding methods, 7, 10, 22
and cancer theory, 9
identification methods, 7, 23
mapping, 9, 24, 25
number, 6, 16, 19
painting, 23
in peripheral blood lymphocytes, 4
in pre-implantation embryos, 61–63
preparation methods, 17–18
sorting, 23
see also cytogenetics
chronic myeloid leukaemia, 9, 106–107
Ciba Foundation symposium, 53, 54, 57
clinical geneticist, consultant, 69
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clinical genetics, 7, 14
services, 3, 14–15, 19–21, 64–65
Clinical Genetics Society, UK, 15, 64, 69
Clinical Research Centre (CRC),
Northwick Park, Harrow, 54, 58
cloning
DNA, 14, 22
positional, 33
codominancy, 27, 107
codon (triplet code), 4, 107
colchicine, 17, 107
collaboration (and sharing), 34, 36–37,
64, 69
colorectal cancer, 9
colour vision/colour blindness, 7, 26
commercial interests, 34, 35
comparative genomic hybridization, 23
computers, 28
conceptual developments, 71
Concerted Action on Genetic Services
in Europe (CAGSE), 65
Confidential Inquiry into Genetic
Counselling by Non-geneticists
(CEGEN), 64
congenital adrenal hyperplasia (CAH;
including 21-hydroxylase deficiency),
30, 31, 107
consanguineous marriage, 31
consultant clinical geneticist, 69
Contact a Family, UK, 69–70
Cooley’s anaemia, 44
see also thalassaemias
Coombs test, 14, 68
copy number, 23, 62
CRC (Clinical Research Centre),
Northwick Park, 54, 58
creatine kinase, 41
Crete, 32
culture media, 48
CVS, see chorionic villus sampling
Cypriot community, London, 44
Cyprus, 44, 47
cystic fibrosis, 10, 107
cytobrush, 49
cytogenetics, 5, 6–11, 14, 15–23, 107
chorionic villus samples, 47, 52
main lines of descent, 7–10
molecular, 22–23
testing, 15, 18–21
see also chromosome(s)
cytotrophoblast, 52, 101, 107
Daily Telegraph, 58
data
availability of raw, 70–71, 72
sharing, 36–37, 64
deletions, 10, 107
18q, 21
Denmark, 15
Department of Health (DoH; formerly
Department of Health and Social
Security; DHSS, until 1988) 33–34, 
64–65, 69, 70
DHSS, see Department of Health
diabetes mellitus, insulin-dependent
(IDDM), 28, 29–30
diakinesis, 16–17, 101
digoxigenin, 22–23, 62
diploid, 107
disjunction, 107
DNA, 4
analysis, prenatal diagnosis, 40
cloning, 14, 22
fetal, in maternal blood, 51
sequencing, 14, 37
DNA arrays, 23
DNA markers, 23, 32–37, 46
DNA probes, 10, 22–23
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DoH, see Department of Health
Down’s syndrome (trisomy 21;
mongolism), 10–11, 101, 113
co-occurrence with Klinefelter’s, 15
cytogenetics, 16–17, 20, 21
diagnostic testing, 19–20
Drosophila sex determination, 7
Duchenne muscular dystrophy, 10, 33,
34, 41, 107
Duffy blood group, 25
duplication, 108
DX 13 probe, 37
Edinburgh, Scotland, 15, 19, 34, 54–55
education, genetics, 64, 65
eggs, hen’s, 21
electron microscopy, 39
electrophoresis, 12–13, 108
elliptocytosis, hereditary, 25
embryo
biopsy, 56–57, 58
research, 53–54, 55–56, 57–59, 60
sexing, 56–57, 58, 60, 61–62
embryonic stem cells, 54–55, 57, 63
endocervical canal, fetal cells in, 49–50,
52
enzymes
in biopsied embryo cells, 56–57
inherited defects, 38–42
pseudodeficiency, 40
erythroblasts, fetal, 50–51
ethical issues, 60, 70
eugenics, 108
movement, 6, 7, 26
prenatal diagnosis and, 63, 70
European Union (EU), 65
exclusion mapping, 36–37
factor VIII, 38, 108
family studies, 28, 32
see also affected sib-pair analysis; 
sib-pair analysis
farming, 4, 6
female
carriers of X-linked disorders, 40–41
Duchenne’s muscular dystrophy, 10, 
33, 34, 41, 107 
pseudohermaphrodite, 15
fetal biopsy, 47
fetal blood sampling, 44–45, 47
fetal cells
in endocervical canal, 49–50, 52
in maternal blood, 50–51
fetal loss rates, prenatal diagnosis, 45, 47
fetoscopy, 47
fibroblasts, cultured, 39
FISH, see fluorescent in situ
hybridization
fluorescent in situ hybridization
(FISH), 10, 42, 50, 108
multicolour, 10, 23
pre-implantation embryos, 61–63
fluorescent probes, 22–23
foods, genetically modified, 4
forensic medicine, 67
fragile site, 108
fragile X (syndrome), 37, 63, 108
Franco–Prussian war (1870–71), 66
G banding (Giemsa banding), 7, 22
Galton Laboratory, London, 14, 15, 42
blood group work, 24, 25, 26
cytogenetics, 18, 19, 20
gamete, 108
Garrod Ward, St Bartholomews's
Hospital, London, 42
Gaucher disease, 39
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Geissen, Germany, 27
gender selection, see sex selection
Genentec, 53
genes, 4
chromosome mapping, 9
defined, 108
isolation/identification, 9, 10
sequencing, 37
genetic code (triplet code), 4, 107
genetic counselling, 30, 33–34
by non-geneticists, 64
Genetics Education (GenEd), 65
Genetic Interest Group, 70
genetic markers, 32–37, 108
genetic medicine, see medical genetics
genetic screening, 108
genetic testing, defined, 3, 108
genetic variation, normal, 42, 65–67
genetically modified foods, 4
genome, 109
linkage markers, 34, 35
Germany, 27, 50, 53
Giemsa banding (G banding), 7, 22
Glasgow, Scotland, 13–14, 17, 19, 20,
21, 34
glassware, handling, 21
β-globin, 13
globin genes, 13–14, 32
α, 60
β, 35
globin-synthesis technique, 13, 49
β-glucosidase, 39
glycogen storage disease type 1, 40
gonadal dysgenesis, pure (Swyer
syndrome), 8, 105
Great Ormond Street, (Hospital for
Sick Children) London, 14, 33, 40, 41
Guy’s Hospital, London, 15, 17, 19,
34, 42
haemoglobin
adult (A), 44
early research, 12–14
electrophoresis, 12
embryonic, 51
fetal, 44
sickle, 12, 13
haemoglobinopathies (haemoglobin
disorders), 11–14
linkage analysis, 32, 33
prenatal diagnosis, 32, 43–46, 48–49
see also sickle-cell diseases;
thalassaemias
haemolytic disease of the newborn, 28
haemophilia, 26, 37, 109
The Haemophilia Society, 37
haemopoiesis, 109
hair root test, 42, 55, 59, 109
Hammersmith Hospital, London, 54,
57, 58
haploid, 108, 109
haplotype, 102
Harperbury Hospital, Shenley, 15
Harwell (MRC Radiobiology Unit),
Didcot, Oxford, 18, 19, 21
hermaphrodite, 15
heterozygous, 30, 41, 109
histochemists, 39
histocompatibility antigens, 63, 64
see also HLA
histologists, 39
HLA, 14, 27, 63–64, 109
disease associations, 29–30, 32
as marker for genetic prediction, 30–31
polymorphism, 29
typing, 53
HLA B27-associated disorders, 29
Home Office, 57–58
Hospital for Sick Children, Great
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Ormond Street, see Great Ormond 
Street
House of Commons, 57, 58–59, 60
Hpa I, 32
HPRT, see hypoxanthine–guanine
phosphoribosyl transferase
Human Fertilization and Embryology
Act, (1990), 53
Human Fertilization and Embryology
Interim Licensing Authority, 57
human genetics, 5
Human Genome Project, 109
human leukocyte antigen, see HLA
Hunter gene, 42
Huntington’s disease (chorea), 24, 33,
69, 109
hybridization
DNA–RNA, 13
in situ, 61
somatic cell, 8–9
21-hydroxylase deficiency, 30, 31, 107
hypervariable regions, 34–35
hypothyroidism, congenital, 41
hypoxanthine–guanine phosphoribosyl
transferase (HPRT), 55, 56, 59
IDDM, see diabetes mellitus, insulin-
dependent
immunogenetics, 43, 63–64
in situ hybridization, 61
in vitro fertilization (IVF), 53, 55, 57
inactive-X hypothesis (Lyon
hypothesis), 8, 110
inborn errors of metabolism, 38–42, 54
Inborn Errors of Metabolism (Garrod),
42, 43
infertility, 10
inheritance, Mendel’s laws, 4
Institute of Child Health, London, 33,
38, 69, 70
Institute of Orthopaedics, Stanmore, 39
insulin, 13
interphase nuclei, 23
Iowa, USA, 36
Italy, 12, 15, 47, 50
IVF, see in vitro fertilization
Jews, Ashkenazi, 41
Johns Hopkins Hospital, Baltimore,
Maryland, USA, 15, 18
karyotype, 108, 109
King’s College Hospital, London, 37, 52
Klinefelter syndrome, 7, 8, 15, 17–18, 
110
co-occurrence with Down’s
syndrome, 15
pre-implantation diagnosis, 62
knockout mouse, 54–55, 57
Knudson’s two-hit hypothesis, 10
Korea, South, 50
Lancet, 46, 48
lay organizations, 36–37, 69–70
Lesch–Nyhan syndrome, 55, 59, 110
leukaemia, chronic myeloid, 9, 106
Lewis blood group, 68
likelihood approach, 28
LINK, 36
linkage, 23–37, 110
analysis methods, 27–28
clinical applications, 26, 28–29,
30–32, 33–34
disequilibrium, 27, 29, 32
DNA markers, 32–37, 46
equilibrium, 27
inequality, 27
non-DNA markers, 23–32
liver biopsy, 39, 40
fetal, 47
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Liverpool, 13, 14, 28, 29, 68
lod score, 28, 110
London, 12, 17, 19, 47, 49, 52
Los Angeles, California, USA, 33
Lund University, Sweden, 21
Lutheran blood group, 25, 110
lymphocytes, peripheral blood, 4, 18, 111
Lyon hypothesis (inactive-X
hypothesis), 8, 110
Lyonization, 8 
see also X inactivation
lysosomal storage disorders, 39, 40
Malaya, 12
malignant disease see cancer
Manchester, 30, 33
MAPH (multiplex amplifiable probe
hybridization), 23
maple syrup urine disease, 39
mass spectrometry, 39
maternal blood
fetal cells in, 50–51
fetal DNA in, 51
Mayo Clinic, Rochester, Minnesota,
USA, 28
media, 57–59
medical genetics, 5, 7, 28, 64–65
Medical Research Council (MRC), 26, 42
Blood Group Unit, 24–25
Experimental Embryology and
Teratology Unit, 54–55
Population Genetics Unit, Oxford, 
18, 21
Radiobiology Unit, Harwell, 18, 19, 21
meiosis, 110
recombination errors in fetu, 11
Melandrium pattern, 8
Mendel’s laws, rediscovery, 4
mental retardation (mental handicap),
3, 10
metabolic diseases, inherited, 38–42, 54
metaphase, 110
microarrays, 23
microsatellites, 37
midwives, 65
mitosis, 110
arrest, with colchicine, 17
molecular cytogenetics, 22–23
molecular genetics, 65, 69
mongolism, see Down’s syndrome
monoclonal antibodies, 9
mosaicism
chromosomal, 8, 106
fetal/maternal tissues, 52
Moscow, Russia, 47
MRC, see Medical Research Council
multiplex amplifiable probe
hybridization (MAPH), 23
Munich, Germany, 27
muscular dystrophy, see Becker
muscular dystrophy; Duchenne
muscular dystrophy; myotonic
muscular dystrophy
mutations, 110
biochemical detection, 38–43
direct identification, 14, 40
myotonic muscular dystrophy, 31
nail-patella syndrome, 25, 26, 111
National Health Service, 68
Nature, 17, 53, 56, 58–59, 71
neonatal screening, 41
nephroblastoma, 9
networks, research workers, 67–68, 69
neurofibromatosis, 36, 70, 111
Neurofibromatosis Association, 36
neuron fatigue, 16
neurons, 15, 16
Neurospora, 42
New York, NY, 24
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New York Academy of Sciences, 44
Newcastle, UK, 21
Nobel Prize for Physiology or
Medicine, 42, 58
nondisjunction, 11, 16
non-geneticist healthcare providers, 64, 65
Northwick Park, Harrow, 51
Nottingham, UK, 23
nucleotide, 23, 111
obstetricians, 18, 46, 65
oocyte, polar body biopsy, 60
oogenesis, 11
ornithine carbamyl transferase
deficiency, 40
ovary, 16
Oxford, UK, 49, 68
cytogenetics, 18, 19, 21
linkage studies, 28, 33, 36
paediatricians, 18
Papilio memnon, 29
Paris, France, 21
patella hammer, 31
pathology departments, 18
patient support groups, 36–37, 69–70
patients, pressure from, 44–45, 46–47,
51, 53, 63, 66
PCR, see polymerase chain reaction
peer review, 58, 71
peptic ulcer, 28
peripheral blood, see blood, peripheral
PGD, see pre-implantation genetic
diagnosis
pharmacogenetics, 22, 43
phenotype, 111
phenylketonuria (PKU), 40, 41, 111
phenylpyruvic acid, urinary, 3
Philadelphia, Pennsylvania, USA, 19, 34
Philadelphia chromosome, 9
phytohaemagglutinin, 18, 111
PKU, see phenylketonuria
plasmids, 22
polar body, 111
biopsy, 60
polycystic kidney disease, 35, 111
polymerase chain reaction (PCR), 10, 
37–38, 111
cross-contamination problem, 61
development, 53, 54
nested, 60
pre-fertilization diagnosis, 60
pre-implantation diagnosis, 56, 57,
58, 59–61
prenatal diagnosis, 46, 50
quantitative fluorescent (QF-PCR), 
50, 112
two-primer, 60
polymorphisms, 32–33, 42, 67, 112
population association studies, 28–30
population structure, normal, 65–67
Portex, 46
Portugal, 35, 50
positional cloning, 33
pre-fertilization genetic diagnosis, 60
pregnancy, termination of, 48, 50
pre-implantation genetic diagnosis
(PGD), 43, 46–47, 53–63
prenatal diagnosis, 10, 43–52, 70
first-trimester, 43–46, 47
haemoglobinopathies, 13, 32, 43–46,
48–49
haemophilia, 37
metabolic diseases, 39–40, 59
non- or minimally invasive methods, 
49–51
using linkage markers, 31, 32
Prenatal Diagnosis, 47, 48, 49
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prenatal screening, 43, 46, 65, 70
primary care, 64, 65
prior probability, 3
probes
DNA, 10, 22–23
DX 13, 37
sharing, 34
quantitative fluorescent polymerase
chain reaction (QF-PCR), 50, 112
quinacrine fluorescent chromosome
banding, 7
R banding, 22
rabbit, 56
recombinant DNA technology, 5, 9,
10, 13–14, 22–23
red blood cell antigens, 24–25
restriction enzyme (restriction
endonuclease), 32, 112
restriction fragment length
polymorphism (RFLP), 32–33, 37, 
112
retinoblastoma, 9–10, 57, 104
RFLP, see restriction fragment length
polymorphism
Rhesus (Rh) blood group system, 24,
25, 68
Rhesus (Rh) haemolytic disease of the
newborn, 28
rheumatic diseases, 29
ribosomal genes, nucleolar, 22
Rockefeller Foundation, New York, 26
Royal College of Pathologists, UK, 64–65
Royal College of Physicians, UK, 64–65
Royal Eastern Counties’ Institution,
Colchester, 3
Royal Free Hospital, London, 37
Runnymede Hotel, near Heathrow, 36
Russia, 47–48
satellite DNA, 22
SCID, see severe combined
immunodeficiency disease
Science, 71
screening
genetic, 102
neonatal, 41
prenatal, 43, 46, 65, 70
Seattle, Washington, USA, 13
secrecy, 34, 70–71
secretor status, 25, 28, 31, 68
Sellafield, Cumbria, 67
severe combined immunodeficiency
disease (SCID), 42, 59, 112
sex chromatin, 7, 15, 16
see chromatin
sex chromosome abnormalities, 7, 25
sex determination, 7–8, 16
sex selection
animal, 55–56
human, 47, 48, 50, 51
sexing, 19
embryo, 56–57, 58, 60, 61–62
fetal, 20, 48, 50, 51
sharing (and collaboration), 34, 36–37,
64, 69
sheep, 6, 55
short tandem repeats (STRs), 50
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